# EDGAR Filing Document

**Accession Number:** 0001671284
**File Stem:** 0001628280-25-038856
**Filing Date:** 2025-8
**Character Count:** 204554
**Document Hash:** e1153a6e42e579b1adcf09b4057fdb83
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001628280-25-038856.hdr.sgml**: 20250807

**ACCESSION NUMBER**: 0001628280-25-038856

**CONFORMED SUBMISSION TYPE**: 10-Q

**PUBLIC DOCUMENT COUNT**: 91

**CONFORMED PERIOD OF REPORT**: 20250630

**FILED AS OF DATE**: 20250807

**DATE AS OF CHANGE**: 20250807

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** NeueHealth, Inc.
- **CENTRAL INDEX KEY:** 0001671284
- **STANDARD INDUSTRIAL CLASSIFICATION:** HOSPITAL & MEDICAL SERVICE PLANS [6324]
- **ORGANIZATION NAME:** 02 Finance
- **EIN:** 474991296
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** 10-Q
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-40537
- **FILM NUMBER:** 251193809

**BUSINESS ADDRESS:**
- **STREET 1:** 9250 NW 36TH STREET
- **STREET 2:** SUITE 420
- **CITY:** DORAL
- **STATE:** FL
- **ZIP:** 33178
- **BUSINESS PHONE:** 612-238-1321

**MAIL ADDRESS:**
- **STREET 1:** 9250 NW 36TH STREET
- **STREET 2:** SUITE 420
- **CITY:** DORAL
- **STATE:** FL
- **ZIP:** 33178

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** Bright Health Group Inc.
- **DATE OF NAME CHANGE:** 20210309

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** Bright Health Inc.
- **DATE OF NAME CHANGE:** 20160404

?xml version='1.0' encoding='ASCII'? bhg-20250630

<u>[**Table of Contents**](#i3110ff974c884b0fab8eec36c8e490a0_7)</u>

**UNITED STATES**

**SECURITIES AND EXCHANGE COMMISSION**

**WASHINGTON, DC 20549**

**FORM 10-Q**

**(Mark One)**

☒ **QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934**

**For the quarterly period ended June 30, 2025**

**OR**

☐ **TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934**

**For the transition period from &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; to &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**

**Commission File Number: 001-40537**

**NEUEHEALTH, INC.**

**(Exact Name of Registrant as Specified in its Charter)**

---

| | |
|:---|:---|
| **Delaware** | **47-4991296** |
| **(State or other jurisdiction of**<br>**incorporation or organization)** | **(I.R.S. Employer**<br>**Identification No.)** |
| **9250 NW 36th St, Suite 420**, **Doral**, **FL** | **33178** |
| **(Address of principal executive offices)** | **(Zip Code)** |

---

**Registrant's telephone number, including area code: (612) 238-1321**

**Securities registered pursuant to Section 12(b) of the Act:**

---

| | | |
|:---|:---|:---|
| **Title of each class**  | **Trading**<br>**Symbol(s)**  | **Name of each exchange**<br>**on which registered**  |
| **Common Stock, $0.0001 par value** | **NEUE** | **New York Stock Exchange** |

---

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.&nbsp;&nbsp;&nbsp;&nbsp;Yes ⌧ No □

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).&nbsp;&nbsp;&nbsp;&nbsp;Yes ⌧&nbsp;&nbsp;&nbsp;&nbsp;No □

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, smaller reporting company, or an emerging growth company. See the definitions of "large accelerated filer," "accelerated filer," "smaller reporting company," and "emerging growth company" in Rule 12b-2 of the Exchange Act.

---

| | | | |
|:---|:---|:---|:---|
| Large accelerated filer | □ | Accelerated filer | □ |
| Non-accelerated filer | ⌧ | Smaller reporting company | ⌧ |
| Emerging growth company | □ |  | |

---

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. □

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). &nbsp;&nbsp;&nbsp;&nbsp; Yes ☐&nbsp;&nbsp;&nbsp;&nbsp;No ⌧

As of August 1, 2025, the registrant had 9,024,240 shares of common stock, $0.0001 par value per share, outstanding.

------

<u>[**Table of Contents**](#i3110ff974c884b0fab8eec36c8e490a0_7)</u>

---

| | | |
|:---|:---|:---|
| <u>[PART I.](#i3110ff974c884b0fab8eec36c8e490a0_13)</u> | <u>[FINANCIAL INFORMATION](#i3110ff974c884b0fab8eec36c8e490a0_13)</u> | <u>[2](#i3110ff974c884b0fab8eec36c8e490a0_13)</u> |
| <u>[Item 1.](#i3110ff974c884b0fab8eec36c8e490a0_16)</u> | <u>[Financial Statements](#i3110ff974c884b0fab8eec36c8e490a0_16)</u> | <u>[2](#i3110ff974c884b0fab8eec36c8e490a0_16)</u> |
|  | <u>[Condensed Consolidated Balance Sheets (Unaudited)](#i3110ff974c884b0fab8eec36c8e490a0_19)</u> | <u>[2](#i3110ff974c884b0fab8eec36c8e490a0_19)</u> |
|  | <u>[Condensed Consolidated Statements of Income (Loss) (Unaudited)](#i3110ff974c884b0fab8eec36c8e490a0_28)</u> | <u>[3](#i3110ff974c884b0fab8eec36c8e490a0_28)</u> |
|  | <u>[Condensed Consolidated Statements of Comprehensive Income (Loss) (Unaudited)](#i3110ff974c884b0fab8eec36c8e490a0_34)</u> | <u>[4](#i3110ff974c884b0fab8eec36c8e490a0_34)</u> |
|  | <u>[Condensed Consolidated Statements of Changes in Redeemable Preferred Stock and Shareholders' Equity (Deficit) (Unaudited)](#i3110ff974c884b0fab8eec36c8e490a0_37)</u> | <u>[5](#i3110ff974c884b0fab8eec36c8e490a0_37)</u> |
|  | <u>[Condensed Consolidated Statements of Cash Flows (Unaudited)](#i3110ff974c884b0fab8eec36c8e490a0_43)</u> | <u>[7](#i3110ff974c884b0fab8eec36c8e490a0_43)</u> |
|  | <u>[Notes to Condensed Consolidated Financial Statements](#i3110ff974c884b0fab8eec36c8e490a0_46)</u> | <u>[8](#i3110ff974c884b0fab8eec36c8e490a0_46)</u> |
| <u>[Item 2.](#i3110ff974c884b0fab8eec36c8e490a0_100)</u> | <u>[Management's Discussion and Analysis of Financial Condition and Results of Operations](#i3110ff974c884b0fab8eec36c8e490a0_100)</u> | <u>[36](#i3110ff974c884b0fab8eec36c8e490a0_100)</u> |
| <u>[Item 3.](#i3110ff974c884b0fab8eec36c8e490a0_133)</u> | <u>[Quantitative and Qualitative Disclosures about Market Risk](#i3110ff974c884b0fab8eec36c8e490a0_133)</u> | <u>[49](#i3110ff974c884b0fab8eec36c8e490a0_133)</u> |
| <u>[Item 4.](#i3110ff974c884b0fab8eec36c8e490a0_136)</u> | <u>[Controls and Procedures](#i3110ff974c884b0fab8eec36c8e490a0_136)</u> | <u>[49](#i3110ff974c884b0fab8eec36c8e490a0_136)</u> |
| <u>[PART II.](#i3110ff974c884b0fab8eec36c8e490a0_139)</u> | <u>[OTHER INFORMATION](#i3110ff974c884b0fab8eec36c8e490a0_139)</u> | <u>[50](#i3110ff974c884b0fab8eec36c8e490a0_139)</u> |
| <u>[Item 1.](#i3110ff974c884b0fab8eec36c8e490a0_142)</u> | <u>[Legal Proceedings](#i3110ff974c884b0fab8eec36c8e490a0_142)</u> | <u>[50](#i3110ff974c884b0fab8eec36c8e490a0_142)</u> |
| <u>[Item 1A.](#i3110ff974c884b0fab8eec36c8e490a0_145)</u> | <u>[Risk Factors](#i3110ff974c884b0fab8eec36c8e490a0_145)</u> | <u>[50](#i3110ff974c884b0fab8eec36c8e490a0_145)</u> |
| <u>[Item 2.](#i3110ff974c884b0fab8eec36c8e490a0_148)</u> | <u>[Unregistered Sales of Equity Securities, Use of Proceeds, and Issuer Purchases of Equity Securities](#i3110ff974c884b0fab8eec36c8e490a0_148)</u> | <u>[50](#i3110ff974c884b0fab8eec36c8e490a0_148)</u> |
| <u>[Item 3.](#i3110ff974c884b0fab8eec36c8e490a0_151)</u> | <u>[Defaults upon Senior Securities](#i3110ff974c884b0fab8eec36c8e490a0_151)</u> | <u>[50](#i3110ff974c884b0fab8eec36c8e490a0_151)</u> |
| <u>[Item 4.](#i3110ff974c884b0fab8eec36c8e490a0_154)</u> | <u>[Mine Safety Disclosures](#i3110ff974c884b0fab8eec36c8e490a0_154)</u> | <u>[50](#i3110ff974c884b0fab8eec36c8e490a0_154)</u> |
| <u>[Item 5.](#i3110ff974c884b0fab8eec36c8e490a0_157)</u> | <u>[Other Information](#i3110ff974c884b0fab8eec36c8e490a0_157)</u> | <u>[50](#i3110ff974c884b0fab8eec36c8e490a0_157)</u> |
| <u>[Item 6.](#i3110ff974c884b0fab8eec36c8e490a0_160)</u> | <u>[Exhibits](#i3110ff974c884b0fab8eec36c8e490a0_160)</u> | <u>[51](#i3110ff974c884b0fab8eec36c8e490a0_160)</u> |

---

i

------

<u>[**Table of Contents**](#i3110ff974c884b0fab8eec36c8e490a0_7)</u>

**FORWARD-LOOKING STATEMENTS**

This Quarterly Report on Form 10-Q contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended (the "Securities Act"), and Section 21E of the Securities Exchange Act of 1934, as amended (the "Exchange Act"). Statements made in this Quarterly Report on Form 10-Q that are not statements of historical fact, including statements about our beliefs and expectations, are forward-looking statements, and should be evaluated as such. Forward-looking statements include any statement or information concerning possible or assumed future results of operations, including descriptions of our business plan and strategies, and our operational and financial outlook, estimates, projections, and guidance. These statements often include words such as "anticipate," "expect," "plan," "believe," "intend," "project," "forecast," "estimates," "projections," "should," "might," "may," "will," "ensure" and other similar expressions. Such forward-looking statements are subject to various risks, uncertainties and assumptions. Accordingly, there are or will be important factors that could cause actual outcomes or results to differ materially from those indicated in these statements. Factors that might materially affect such forward-looking statements include: our ability to continue as a going concern; expectations and outcomes related to the NEA Merger Agreement (as defined below); our ability to comply with the terms of our credit facilities or any credit facility into which we enter in the future; our ability to obtain any short or long-term debt or equity financing needed to operate our business; our ability to quickly and efficiently complete the wind down of our remaining Individual and Family Plan ("IFP") businesses and MA businesses, including by satisfying liabilities of those businesses when due and payable; potential disruptions to our business due to corporate restructuring and any resulting headcount reduction; our ability to accurately estimate and effectively manage the costs relating to changes in our business offerings and models; a delay or inability to withdraw regulated capital from our subsidiaries; a lack of acceptance or slow adoption of our business model; our ability to retain existing consumers and expand consumer enrollment; our Care Partners' abilities to obtain and accurately assess, code, and report risk adjustment factor scores; our ability to contract with care providers and arrange for the provision of quality care; our ability to obtain claims information timely and accurately; the impact of any pandemic or epidemic on our business and results of operations; the risks associated with our reliance on third-party providers to operate our business; the impact of modifications or changes to the U.S. health insurance markets; the impact of changes to federal funding for government healthcare programs; our ability to manage any growth of our business; our ability to operate, update or implement our technology platform and other information technology systems; our ability to retain key executives; our ability to successfully pursue acquisitions, integrate acquired businesses and divest businesses as needed; the occurrence of severe weather events, catastrophic health events, natural or man-made disasters, and social and political conditions or civil unrest; our ability to prevent and contain data security incidents and the impact of data security incidents on our members, patients, employees and financial results; our ability to comply with requirements to maintain effective internal controls; the outcome of threatened or pending litigation and risks of future legal disputes; the impacts resulting from new (or change to existing) laws, regulations and executive actions; our ability to mitigate risks associated with our Accountable Care Organizations ("ACO") Realizing Equity, Access, and Community Health ("REACH") businesses, including any unanticipated market or legislative or regulatory developments; and the other factors set forth under the heading "Risk Factors" in our Annual Report on Form 10-K for the year ended December 31, 2024, that was filed with the SEC on March 21, 2025 ("2024 Form 10-K") and our other filings with the SEC.

The preceding list is not intended to be an exhaustive list of all of the factors that might affect our forward-looking statements. The forward-looking statements are based on our beliefs, assumptions and expectations of future performance, taking into account the information currently available to us. These statements are only predictions based upon our current expectations and projections about future events. There are important factors that could cause our actual results, level of activity, performance or achievements to differ materially from the results, level of activity, performance or achievements expressed or implied by the forward-looking statements. Other sections of this Quarterly Report on Form 10-Q may include additional factors that could adversely impact our business and financial performance. Moreover, we operate in a very competitive and rapidly changing environment. New risks emerge from time to time and it is not possible for our management to predict all risks, nor can we assess the impact of all factors on our business or the extent to which any factor, or combination of factors, may cause actual results to differ materially from those contained in any forward-looking statements we may make.

You should not rely upon forward-looking statements as predictions of future events. Our forward-looking statements speak only as of the date of this Quarterly Report on Form 10-Q and, although we believe that the expectations reflected in the forward-looking statements are reasonable, we cannot guarantee that the future results, levels of activity, performance and events and circumstances reflected in such forward-looking statements will be achieved or occur at all. Except as required by law, we undertake no obligation to update publicly any forward-looking statements for any reason after the date of this release to conform these statements to actual results or to changes in our expectations.

------

<u>[**Table of Contents**](#i3110ff974c884b0fab8eec36c8e490a0_7)</u>

**PART I. FINANCIAL INFORMATION**

**Item 1. Financial Statements**

**NeueHealth, Inc. and Subsidiaries**

**Condensed Consolidated Balance Sheets**

*(in thousands, except share and per share data)*

**(Unaudited)**

---

| | | |
|:---|:---|:---|
| | **June 30,<br>2025** | **December 31,<br>2024** |
| **Assets** | | |
| Current assets: |  |  |
| &nbsp;&nbsp;&nbsp;Cash and cash equivalents | $131618 | $83295 |
| &nbsp;&nbsp;&nbsp;Short-term investments | 13946 | 9871 |
| &nbsp;&nbsp;&nbsp;Accounts receivable, net of allowance of $55 and $27, respectively | 53074 | 36594 |
| &nbsp;&nbsp;&nbsp;ACO REACH performance year receivable | 321596 | 95075 |
| &nbsp;&nbsp;&nbsp;Current assets of discontinued operations (Note 14) | 89804 | 173006 |
| &nbsp;&nbsp;&nbsp;Prepaids and other current assets | 29844 | 36807 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**Total current assets** | 639882 | 434648 |
| Other assets: |  |  |
| &nbsp;&nbsp;&nbsp;Property, equipment and capitalized software, net | 11664 | 11240 |
| &nbsp;&nbsp;&nbsp;Intangible assets, net | 66088 | 71064 |
| &nbsp;&nbsp;&nbsp;Other non-current assets | 26055 | 27431 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**Total other assets** | 103807 | 109735 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**Total assets** | $743689 | $544383 |
| **Liabilities, Redeemable Noncontrolling Interest, Redeemable Preferred Stock and Shareholders' Equity (Deficit)** |  |  |
| Current liabilities: |  |  |
| &nbsp;&nbsp;&nbsp;Medical costs payable | $97837 | $124360 |
| &nbsp;&nbsp;&nbsp;Accounts payable | 5317 | 6298 |
| &nbsp;&nbsp;&nbsp;Short-term borrowings | 1000 | 2000 |
| &nbsp;&nbsp;&nbsp;ACO REACH performance year obligation | 248465 |  |
| &nbsp;&nbsp;&nbsp;Current liabilities of discontinued operations (Note 14) | 333799 | 344651 |
| &nbsp;&nbsp;&nbsp;Risk share payable to deconsolidated entity | 123981 | 123981 |
| &nbsp;&nbsp;&nbsp;Warrant liability | 27651 | 29738 |
| &nbsp;&nbsp;&nbsp;Other current liabilities | 70362 | 79200 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**Total current liabilities** | 908412 | 710228 |
| Long-term borrowings | 212433 | 202614 |
| Other liabilities | 15899 | 17649 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**Total liabilities** | 1136744 | 930491 |
| Commitments and contingencies (Note 8) |  |  |
| Redeemable noncontrolling interests | 55729 | 48580 |
| Redeemable Series A preferred stock, $0.0001 par value; 750,000 shares authorized in 2025 and 2024; 750,000 shares issued and outstanding in 2025 and 2024 | 747481 | 747481 |
| Redeemable Series B preferred stock, $0.0001 par value; 175,000 shares authorized in 2025 and 2024; 175,000 shares issued and outstanding in 2025 and 2024 | 172936 | 172936 |
| Shareholders' equity (deficit): |  |  |
| Common stock, $0.0001 par value; 3,000,000,000 shares authorized in 2025 and 2024; 9,024,240 and 8,320,959 shares issued and outstanding in 2025 and 2024, respectively | 1 | 1 |
| &nbsp;&nbsp;&nbsp;Additional paid-in capital | 3107121 | 3099423 |
| &nbsp;&nbsp;&nbsp;Accumulated deficit | (4464323) | (4442529) |
| &nbsp;&nbsp;&nbsp;Accumulated other comprehensive loss |  |  |
| Treasury Stock, at cost, 31,526 shares at June 30, 2025, and December 31, 2024, respectively | (12000) | (12000) |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**Total shareholders' equity (deficit)** | (1369201) | (1355105) |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**Total liabilities, redeemable noncontrolling interests, redeemable preferred stock and shareholders' equity (deficit)** | $743689 | $544383 |

---

See accompanying Notes to Condensed Consolidated Financial Statements

------

<u>[**Table of Contents**](#i3110ff974c884b0fab8eec36c8e490a0_7)</u>

**NeueHealth, Inc. and Subsidiaries**

**Condensed Consolidated Statements of Income (Loss)**

*(in thousands, except per share data)*

**(Unaudited)**

---

| | | | | |
|:---|:---|:---|:---|:---|
| | **Three Months Ended<br>June 30,** | **Three Months Ended<br>June 30,** | **Six Months Ended<br>June 30,** | **Six Months Ended<br>June 30,** |
| | **2025** | **2024** | **2025** | **2024** |
| Revenue: |  |  |  |  |
| &nbsp;&nbsp;Capitated revenue | $82532 | $64005 | $163519 | $125471 |
| &nbsp;&nbsp;ACO REACH revenue | 115339 | 149802 | 239379 | 321613 |
| &nbsp;&nbsp;Service revenue | 10420 | 12076 | 20254 | 23691 |
| &nbsp;&nbsp;Investment income | 791 | 108 | 1717 | 311 |
| &nbsp;&nbsp;&nbsp;&nbsp;**Total revenue** | 209082 | 225991 | 424869 | 471086 |
| Operating expenses: |  |  |  |  |
| &nbsp;&nbsp;Medical costs | 146410 | 177681 | 307304 | 374555 |
| &nbsp;&nbsp;Operating costs | 44860 | 70470 | 93533 | 137231 |
| &nbsp;&nbsp;Intangible assets impairment |  | 11411 |  | 11411 |
| &nbsp;&nbsp;Depreciation and amortization | 3555 | 3978 | 7114 | 8540 |
| &nbsp;&nbsp;&nbsp;&nbsp;**Total operating expenses** | 194825 | 263540 | 407951 | 531737 |
| &nbsp;&nbsp;&nbsp;&nbsp;**Operating income (loss)** | 14257 | (37549) | 16918 | (60651) |
| &nbsp;&nbsp;Interest expense | 6878 | 4110 | 13515 | 7040 |
| &nbsp;&nbsp;Warrant expense (income) | 562 | (2213) | (2087) | (4285) |
| &nbsp;&nbsp;Gain on troubled debt restructuring |  |  |  | (30311) |
| &nbsp;&nbsp;&nbsp;&nbsp;**Income (Loss) from continuing operations before income taxes** | 6817 | (39446) | 5490 | (33095) |
| Income tax (benefit) expense | (21) | (187) | 90 | 476 |
| &nbsp;&nbsp;**Net income (loss) from continuing operations** | 6838 | (39259) | 5400 | (33571) |
| &nbsp;&nbsp;Loss from discontinued operations, net of tax (Note 14) | (8386) | (18439) | (17796) | (28304) |
| **Net Loss** | (1548) | (57698) | (12396) | (61875) |
| &nbsp;&nbsp;Net income from continuing operations attributable to noncontrolling interests | (8507) | (932) | (9398) | (12669) |
| &nbsp;&nbsp;Series A preferred stock dividend accrued | (10981) | (10422) | (21710) | (20716) |
| &nbsp;&nbsp;Series B preferred stock dividend accrued | (2465) | (2338) | (4872) | (4648) |
| &nbsp;&nbsp;&nbsp;&nbsp;**Net loss attributable to NeueHealth, Inc. common shareholders** | $(23501) | $(71390) | $(48376) | $(99908) |
| **Basic and diluted loss per share attributable to NeueHealth, Inc. common shareholders** |  |  |  |  |
| &nbsp;&nbsp;Continuing operations | $(1.68) | $(6.42) | $(3.49) | $(8.77) |
| &nbsp;&nbsp;Discontinued operations | (0.94) | (2.23) | (2.04) | (3.46) |
| &nbsp;&nbsp;Basic and diluted loss per share | $(2.62) | $(8.65) | $(5.53) | $(12.23) |
| Basic and diluted weighted-average common shares outstanding | 8978 | 8253 | 8750 | 8166 |

---

See accompanying Notes to Condensed Consolidated Financial Statements

------

<u>[**Table of Contents**](#i3110ff974c884b0fab8eec36c8e490a0_7)</u>

**NeueHealth, Inc. and Subsidiaries**

**Condensed Consolidated Statements of Comprehensive Income (Loss)**

*(in thousands)*

**(Unaudited)**

---

| | | | | |
|:---|:---|:---|:---|:---|
| | **Three Months Ended<br>June 30,** | **Three Months Ended<br>June 30,** | **Six Months Ended<br>June 30,** | **Six Months Ended<br>June 30,** |
| | **2025** | **2024** | **2025** | **2024** |
| **Net loss** | $(1548) | $(57698) | $(12396) | $(61875) |
| Other comprehensive income: |  |  |  |  |
| Unrealized investment holding gains arising during the year, net of tax of $0 and $0, respectively |  | 100 |  | 120 |
| Less: reclassification adjustments for investment gains, net of tax of $0 and $0, respectively |  | (4) |  | (2) |
| Other comprehensive income |  | 104 |  | 122 |
| Comprehensive loss | (1548) | (57594) | (12396) | (61753) |
| Comprehensive income attributable to noncontrolling interests | (8507) | (932) | (9398) | (12669) |
| **Comprehensive loss attributable to NeueHealth, Inc. common shareholders** | $(10055) | $(58526) | $(21794) | $(74422) |

---

See accompanying Notes to Condensed Consolidated Financial Statements

------

<u>[**Table of Contents**](#i3110ff974c884b0fab8eec36c8e490a0_7)</u>

**NeueHealth, Inc. and Subsidiaries**

**Condensed Consolidated Statements of Changes in Redeemable Preferred Stock and Shareholders' Equity (Deficit)**

*(in thousands)*

**(Unaudited)**

---

| | | | | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|:---|:---|:---|
| | **Redeemable Preferred Stock** | **Redeemable Preferred Stock** | **Common Stock** | **Common Stock** | **Additional<br>Paid-In<br>Capital** | **Retained<br>Earnings<br>(Deficit)** | **Accumulated<br>Other<br>Comprehensive<br>Income (Loss)** | **Treasury Stock** | **Total** |
| **2025** | **Shares** | **Amount** | **Shares** | **Amount** | **Additional<br>Paid-In<br>Capital** | **Retained<br>Earnings<br>(Deficit)** | **Accumulated<br>Other<br>Comprehensive<br>Income (Loss)** | **Treasury Stock** | **Total** |
| **Balance at January 1, 2025** | 925 | $920417 | 8321 | $1 | $3099423 | $(4442529) | $— | $(12000) | $(1355105) |
| &nbsp;&nbsp;&nbsp;Net loss |  |  |  |  |  | (11739) |  |  | (11739) |
| &nbsp;&nbsp;&nbsp;Issuance of common stock |  |  | 607 |  |  |  |  |  |  |
| &nbsp;&nbsp;&nbsp;Share-based compensation |  |  |  |  | 5686 |  |  |  | 5686 |
| **Balance at March 31, 2025** | 925 | $920417 | 8928 | $1 | $3105109 | $(4454268) | $— | $(12000) | $(1361158) |
| &nbsp;&nbsp;&nbsp;Net loss |  | $— |  | $— | $— | $(10055) | $— | $— | $(10055) |
| &nbsp;&nbsp;&nbsp;Issuance of common stock |  |  | 96 |  |  |  |  |  |  |
| &nbsp;&nbsp;&nbsp;Share-based compensation |  |  |  |  | 2012 |  |  |  | 2012 |
| **Balance at June 30, 2025** | 925 | $920417 | 9024 | $1 | $3107121 | $(4464323) | $— | $(12000) | $(1369201) |

---

See accompanying Notes to Condensed Consolidated Financial Statements

------

<u>[**Table of Contents**](#i3110ff974c884b0fab8eec36c8e490a0_7)</u>

**NeueHealth, Inc. and Subsidiaries**

**Condensed Consolidated Statements of Changes in Redeemable Preferred Stock and Shareholders' Equity (Deficit)**

*(in thousands)*

**(Unaudited)**

---

| | | | | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|:---|:---|:---|
| | **Redeemable Preferred Stock** | **Redeemable Preferred Stock** | **Common Stock** | **Common Stock** | **Additional<br>Paid-In<br>Capital** | **Retained<br>Earnings<br>(Deficit)** | **Accumulated<br>Other<br>Comprehensive<br>Income (Loss)** | **Treasury Stock** | **Total** |
| **2024** | **Shares** | **Amount** | **Shares** | **Amount** | **Additional<br>Paid-In<br>Capital** | **Retained<br>Earnings<br>(Deficit)** | **Accumulated<br>Other<br>Comprehensive<br>Income (Loss)** | **Treasury Stock** | **Total** |
| **Balance at January 1, 2024** | 925 | $920417 | 8054 | $1 | $3056027 | $(4307849) | $(122) | $(12000) | $(1263943) |
| &nbsp;&nbsp;&nbsp;Net loss |  |  |  |  |  | (15914) |  |  | (15914) |
| &nbsp;&nbsp;&nbsp;Issuance of common stock |  |  | 171 |  |  |  |  |  |  |
| &nbsp;&nbsp;&nbsp;Share-based compensation |  |  |  |  | 18627 |  |  |  | 18627 |
| &nbsp;&nbsp;&nbsp;Other comprehensive income |  |  |  |  |  |  | 18 |  | 18 |
| **Balance at March 31, 2024** | 925 | $920417 | 8225 | $1 | $3074654 | $(4323763) | $(104) | $(12000) | $(1261212) |
| &nbsp;&nbsp;&nbsp;Net loss |  | $— |  | $— | $— | $(58630) | $— | $— | $(58630) |
| &nbsp;&nbsp;&nbsp;Issuance of common stock |  |  | 54 |  |  |  |  |  |  |
| &nbsp;&nbsp;&nbsp;Share-based compensation |  |  |  |  | 18779 |  |  |  | 18779 |
| &nbsp;&nbsp;&nbsp;Equity-classified warrants issued |  |  |  |  | 1157 |  |  |  | 1157 |
| &nbsp;&nbsp;&nbsp;Equity distributions to noncontrolling interest holders |  |  |  |  | (7020) |  |  |  | (7020) |
| &nbsp;&nbsp;&nbsp;Other comprehensive income |  |  |  |  |  |  | 104 |  | 104 |
| **Balance at June 30, 2024** | 925 | $920417 | 8279 | $1 | $3087570 | $(4382393) | $— | $(12000) | $(1306822) |

---

See accompanying Notes to Condensed Consolidated Financial Statements

------

<u>[**Table of Contents**](#i3110ff974c884b0fab8eec36c8e490a0_7)</u>

**NeueHealth, Inc. and Subsidiaries**

**Condensed Consolidated Statements of Cash Flows**

*(in thousands)*

**(Unaudited)**

---

| | | |
|:---|:---|:---|
| | **Six Months Ended June 30,** | **Six Months Ended June 30,** |
| | **2025** | **2024** |
| Cash flows from operating activities: |  |  |
| &nbsp;&nbsp;&nbsp;Net loss | $(12396) | $(61875) |
| &nbsp;&nbsp;&nbsp;Adjustments to reconcile net loss to net cash provided by operating activities: |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Depreciation and amortization | 7114 | 8540 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Impairment of intangible assets |  | 11411 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Share-based compensation | 7497 | 37407 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Payment-in-kind "PIK" interest | 8952 |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Gain on troubled debt restructuring |  | (30311) |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Net accretion of investments | (202) | (72) |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Loss on disposal of property, equipment, and capitalized software | 87 | 595 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Other, net | 1029 | (469) |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Changes in assets and liabilities, net of acquired assets and liabilities: |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Accounts receivable | (16480) | (4872) |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;ACO REACH performance year receivable | (226521) | (309639) |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Other assets | 9567 | (7889) |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Medical cost payable | (31421) | (35998) |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Risk adjustment payable | (4996) | (4155) |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Accounts payable and other liabilities | (12483) | (14387) |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Unearned revenue |  | (11) |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Warrant liability | (2087) | 8978 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;ACO Reach performance year obligation | 248465 | 325599 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**Net cash used in operating activities** | (23875) | (77148) |
| Cash flows from investing activities: |  |  |
| &nbsp;&nbsp;&nbsp;Purchases of investments | (8224) | (9544) |
| &nbsp;&nbsp;&nbsp;Proceeds from sales, paydowns, and maturities of investments | 4388 | 2581 |
| &nbsp;&nbsp;&nbsp;Purchases of property and equipment | (2653) | (877) |
| &nbsp;&nbsp;&nbsp;Proceeds from sale of business, net | 61139 | 197121 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**Net cash provided by investing activities** | 54650 | 189281 |
| &nbsp;&nbsp;&nbsp;Cash flows from financing activities: |  |  |
| &nbsp;&nbsp;&nbsp;Proceeds from long-term borrowings |  | 52411 |
| &nbsp;&nbsp;&nbsp;Repayments of short-term borrowings | (1000) | (273636) |
| &nbsp;&nbsp;&nbsp;Distributions to noncontrolling interest holders | (2249) | (4730) |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**Net cash used in financing activities** | (3249) | (225955) |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**Net increase (decrease) in cash and cash equivalents** | 27526 | (113822) |
| Cash and cash equivalents of total operations – beginning of year | 185405 | 375280 |
| Cash and cash equivalents of total operations – end of period | $212931 | $261458 |
| **Supplemental disclosures of cash flow information:** |  |  |
| Changes in unrealized gain on available-for-sale securities in OCI |  | 122 |

---

See accompanying Notes to Condensed Consolidated Financial Statements

------

<u>[**Table of Contents**](#i3110ff974c884b0fab8eec36c8e490a0_7)</u>

**NeueHealth, Inc.**

**Notes to Condensed Consolidated Financial Statements**

**(Unaudited)**

**NOTE 1. ORGANIZATION AND BASIS OF PRESENTATION**

**Organization:** NeueHealth, Inc. and subsidiaries (collectively, "NeueHealth," "we," "our," "us," or the "Company") was founded in 2015 to transform healthcare. NeueHealth is a value-driven, consumer-centric healthcare company committed to making high-quality, coordinated healthcare accessible and affordable to all populations. We believe we can reduce the friction and current lack of coordination in today's healthcare system by uniquely aligning the interests of payors and providers to enable a seamless, consumer-centric healthcare experience that drives value for all.

We have two market facing segments: NeueCare and NeueSolutions. NeueCare is our value-driven care delivery business that manages risk in partnership with external payors and serves all populations across The Patient Protection and Affordable Care Act and the Health Care and Education Reconciliation Act of 2010 ("ACA") Marketplace, Medicare, and Medicaid. NeueSolutions is our provider enablement business that includes a suite of technology, services, and clinical care solutions that empower providers to thrive in performance-based arrangements.

**Basis of Presentation:** The condensed consolidated financial statements include the accounts of NeueHealth, Inc. and all subsidiaries and controlled companies. All intercompany balances and transactions are eliminated upon consolidation. The condensed consolidated financial statements are prepared in accordance with accounting principles generally accepted in the United States of America ("GAAP") for interim financial reporting. Accordingly, they do not include all of the information and footnotes required by GAAP for annual financial statements. We have omitted certain footnote disclosures that would substantially duplicate the disclosures in our audited consolidated financial statements, unless the information contained in those disclosures materially changed or is required by GAAP. As such, the condensed consolidated financial statements should be read in conjunction with our audited consolidated financial statements and the related notes thereto as of and for the year ended December 31, 2024 included in our Form 10-K for the year ended December 31, 2024 ("2024 Form 10-K"). The accompanying condensed consolidated financial statements include all normal recurring adjustments necessary for fair presentation of the interim financial statements.

**Medicare Shared Savings Program:** Beginning January 1, 2025 our NeueSolutions reporting segment began participating in the Centers for Medicare & Medicaid Services' ("CMS") Medicare Shared Savings Program ("MSSP"). As part of our MSSP participation we elected a July 1, 2025 start date to begin participating in the ACO Primary Care Flex Model ("ACO PC Flex Model") payment mechanism, a test initiative within the MSSP.

The MSSP was created to promote accountability and improve coordination of care for Medicare beneficiaries. For each ACO participating in the MSSP, CMS develops a benchmark for savings to be achieved by each ACO. An ACO that meets the MSSP's quality performance standards will be eligible to receive a share of the savings to the extent its assigned beneficiary medical expenditures are below the medical expenditure benchmark provided by CMS. A Minimum Savings Rate ("MSR") must be achieved before the ACO can receive a share of the savings. Once the MSR is surpassed, all the savings below the benchmark provided by CMS will be shared at a certain percentage with the ACO. The MSR varies depending on the number of beneficiaries assigned to the ACO. The ACO PC Flex Model is a five-year voluntary model test within the MSSP that shifts payment for primary care away from fee-for-service ("FFS") payments to monthly Prospective Primary Care ("PPC") payments.

Our MSSP Aligned Beneficiaries will receive services from physicians and other medical service providers, both in-network and out-of-network. CMS continues to pay participants and preferred providers on a FFS basis for Medicare-covered services provided to MSSP Aligned Beneficiaries. The Company continues to bear partial risk on all Medicare expenditures (both in-network and out-of-network), excluding drug expenditures covered by Medicare Part D, based on a budgetary benchmark established with CMS. Due to the partial risk profile, we apply net revenue recognition in accordance with Accounting Standards Codification ("ASC") 606, Revenue from Contracts With Customers ("ASC 606"). We have elected to participate in the ENHANCED risk track of the MSSP, which makes us eligible to receive the surplus ("shared savings") or liable for the deficit ("shared losses") according to the budgetary benchmark established by CMS. Our shared savings or shared losses will be determined annually after the performance year reconciliation with CMS. We recognize shared savings revenue under the MSSP only when amounts are measurable and enforceable and it is unlikely significant reversal will occur, typically upon notification from CMS upon meeting savings benchmarks. When the MSR is achieved, the revenue recognized for our share of the savings is recorded on a net basis. We recognize shared losses under the MSSP when the amount is probable and estimable.

------

<u>[**Table of Contents**](#i3110ff974c884b0fab8eec36c8e490a0_7)</u>

**NeueHealth, Inc.**

**Notes to Condensed Consolidated Financial Statements**

**(Unaudited)**

We recognize MSSP revenue within capitated revenue in the condensed consolidated statements of income (loss). For the three and six months ended June 30, 2025 $1.1 million of MSSP revenue was recognized within our NeueSolutions segment. For the three and six months ended June 30, 2024, no MSSP revenue was recognized.

**NEA Merger Agreement:** On December 23, 2024, NeueHealth entered into the NEA Merger Agreement with NH Holdings 2025, Inc., a Delaware corporation ("Parent"), pursuant to which, and subject to the conditions set forth therein, the Company will become a wholly owned subsidiary of Parent (the "NEA Merger"). Parent is indirectly controlled by private investment funds affiliated with New Enterprise Associates, Inc.

The completion of the NEA Merger is subject to the fulfillment or waiver of certain customary mutual closing conditions, including (a) the adoption of the NEA Merger Agreement by the affirmative vote of the holders of a majority of the voting power of the outstanding shares of Company Common Stock and Company Preferred Stock (voting on an as-converted basis), voting together as a single class, that are entitled to vote thereon (the "Company Stockholder Approval"), (b) the absence of any law or order prohibiting, enjoining or making illegal the consummation of the NEA Merger and (c) all specified regulatory filings and approvals required in connection with the transactions contemplated by the NEA Merger Agreement having been made or received, as applicable. The obligation of each party to consummate the NEA Merger is also subject to the fulfillment or waiver of certain customary unilateral closing conditions, including the other party's (or parties') representations and warranties being true and correct (subject to certain customary materiality qualifiers) and the other party (or parties) having performed in all material respects its (or their) obligations under the NEA Merger Agreement. The obligation of each of Parent and Merger Sub to consummate the NEA Merger is additionally conditioned upon there not having been imposed any Burdensome Condition (as defined in the NEA Merger Agreement) in connection with the receipt of the regulatory approvals required in connection with the transactions contemplated by the NEA Merger Agreement.

On May 7, 2025, we obtained the Company Stockholder Approval of the NEA Merger Agreement. The remaining required closing conditions have yet to be obtained, and there is no assurance that all of them will be obtained.

**Use of Estimates:** The preparation of our condensed consolidated financial statements in conformance with GAAP requires management to make estimates and assumptions that affect the reported amounts in the condensed consolidated financial statements and accompanying notes. Our most significant estimates include medical costs payable, provider risk share arrangements, third-party payor risk share arrangements, and valuation and impairment of intangible assets. Actual results could differ from these estimates.

**Going Concern:** The condensed consolidated financial statements have been prepared in accordance with GAAP applicable to a going concern, which contemplates the realization of assets and the satisfaction of liabilities in the normal course of business.

The Company has a history of generating net losses, and for the six months ended June 30, 2025 we generated a net loss of $12.4 million. Additionally, the Company experienced negative operating cash flows for the six months ended June 30, 2025. Certain of the Company's insurance subsidiaries have material risk adjustment program obligations remaining related to the Company's discontinued commercial insurance business, totaling $271.8 million, as noted further in Note 14, *Discontinued Operations*.

Cash and investment balances held at regulated insurance entities are subject to regulatory restrictions and can only be accessed through dividends declared to the non-regulated parent company or through reimbursements from administrative services agreements with the parent company. The regulated legal entities are required to hold certain minimum levels of risk-based capital and surplus to meet regulatory requirements. As noted further in Note 14, *Discontinued Operations*, we are out of compliance with the minimum levels for certain of our regulated insurance legal entities. In certain of our other regulated insurance legal entities, we hold surplus levels of risk-based capital, and as we complete the wind-down exercise related to these entities, we expect to recapture through dividends and final liquidation actions the remaining cash positions of these entities.

We believe that the existing cash and investments will not be sufficient to satisfy our anticipated cash requirements for the next twelve months following the date the condensed consolidated financial statements contained in this Quarterly Report on Form 10-Q are issued. These conditions raise substantial doubt about the Company's ability to continue as a going concern.

------

<u>[**Table of Contents**](#i3110ff974c884b0fab8eec36c8e490a0_7)</u>

**NeueHealth, Inc.**

**Notes to Condensed Consolidated Financial Statements**

**(Unaudited)**

In response to these conditions, management continues to implement plans to drive positive operating cash flow and achieve the requirements in the existing debt agreements to access additional liquidity. However, the Company may not be able to access other tranches of the loan and security agreement with Hercules Capital, Inc., and may not be able to recapture through dividends additional cash from its regulated insurance entities, as these matters are all subject to conditions that are not fully within the Company's control.

Given these plans are subject to conditions that are not fully within the Company's control, the Company forecasts that it will be unable to satisfy its obligations. As a result, the Company has concluded that management's plans do not alleviate substantial doubt about the Company's ability to continue as a going concern.

The condensed consolidated financial statements do not include any adjustments relating to the recoverability and classification of recorded asset amounts or the amounts and classification of liabilities that might result from the outcome of this uncertainty.

**Recently Issued and Adopted Accounting Pronouncements:** There are no accounting pronouncements that were recently issued and not yet adopted or adopted since our audited consolidated financial statements were issued that had, or are expected to have, a material impact on our consolidated financial position, results of operations, or cash flows.

**NOTE 2. INTANGIBLE ASSETS**

The carrying values and accumulated amortization for definite-lived intangible assets were as follows *(in thousands)*:

---

| | | | | |
|:---|:---|:---|:---|:---|
| **June 30, 2025** | **Weighted Average Life (years)** | **Gross Carrying <br>Amount** | **Accumulated <br>Amortization** | **Net Carrying Amount** |
| Customer relationships | 5.1 | $68770 | $32482 | $36288 |
| Trade names | 10.9 | 40900 | 11100 | 29800 |
| &nbsp;&nbsp;Total |  | $109670 | $43582 | $66088 |

---

---

| | | | | |
|:---|:---|:---|:---|:---|
| **December 31, 2024** | **Weighted Average Life (years)** | **Gross Carrying <br>Amount** | **Accumulated <br>Amortization** | **Net Carrying Amount** |
| Customer relationships | 5.6 | $68770 | $28869 | $39901 |
| Trade names | 11.5 | 40900 | 9737 | 31163 |
| &nbsp;&nbsp;Total |  | $109670 | $38606 | $71064 |

---

There were no impairments to or disposals of definite-lived intangible assets recognized for the three and six months ended June 30, 2025 and there was $11.4 million of impairments for the three and six months ended June 30, 2024.

We are continuously evaluating whether events or changes in circumstances indicate that an intangible asset may not be recoverable including an adverse change in the extent in which an intangible asset is used, our market capitalization, macroeconomic trends, and other events and uncertainties. Negative trends in these factors could result in a non-cash charge for impairment to intangible assets in a future period.

Amortization expense relating to definite-lived intangible assets for the three months ended June 30, 2025 and 2024 was $2.5 million and $2.9 million, respectively. Amortization expense for the six months ended June 30, 2025 and 2024 was

------

<u>[**Table of Contents**](#i3110ff974c884b0fab8eec36c8e490a0_7)</u>

**NeueHealth, Inc.**

**Notes to Condensed Consolidated Financial Statements**

**(Unaudited)**

$5.0 million and $5.8 million, respectively. Estimated amortization expense relating to definite-lived intangible assets for the remainder of 2025 and for each of the next five full years ending December 31 is as follows *(in thousands)*:

---

| | |
|:---|:---|
| 2025 (July-December) | $4976 |
| 2026 | $9952.0 |
| 2027 | $9952.0 |
| 2028 | $8673.0 |
| 2029 | $8673.0 |
| 2030 | $8673.0 |

---

**NOTE 3. MEDICAL COSTS PAYABLE**

The following table shows the components of the change in medical costs payable for the six months ended June 30, 2025 and 2024 *(in thousands)*:

---

| | | |
|:---|:---|:---|
| | **June 30,** | **June 30,** |
| | **2025** | **2024** |
| Medical costs payable - January 1 | $124360 | $157903 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Incurred related to: |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Current year | 311680 | 380782 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Prior year | (4376) | (6227) |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Total incurred | 307304 | 374555 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Paid related to: |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Current year | 242234 | 277748 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Prior year | 91594 | 117666 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Total paid | 333828 | 395414 |
| Medical costs payable - June 30 | $97837 | $137044 |

---

Medical costs payable attributable to prior years decreased by $4.4 million and $6.2 million for the six months ended June 30, 2025 and 2024, respectively. Medical costs payable estimates are adjusted as additional information regarding claims becomes known; there were no significant changes to estimation methodologies during the periods. Medical costs payable as of June 30, 2025 are primarily related to the current year.

------

<u>[**Table of Contents**](#i3110ff974c884b0fab8eec36c8e490a0_7)</u>

**NeueHealth, Inc.**

**Notes to Condensed Consolidated Financial Statements**

**(Unaudited)**

The table below details the components making up the medical costs payable as of June 30, 2025 and December 31, 2024 *(in thousands)*:

---

| | | |
|:---|:---|:---|
| | **June 30, 2025** | **December 31, 2024** |
| Claims unpaid | $874 | $638 |
| Payables due to CMS <sup>(1)</sup> | 18090 | 17846 |
| Provider incentive payable | 13853 | 15985 |
| Incurred but not reported (IBNR) | 65021 | 89891 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Total medical costs payable | $97837 | $124360 |

---

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<sup>(1) &nbsp;&nbsp;&nbsp;&nbsp;</sup>Payables due to CMS primarily relate to out-of-network claims the Company is required to pay as a result of our ACO REACH Care Partner, Babylon, filing for bankruptcy.

**NOTE 4. BORROWINGS AND COMMON STOCK WARRANTS**

**Short-term Borrowings and Troubled Debt Restructuring:** In March 2021, we entered into a $350.0 million revolving credit agreement with JPMorgan Chase Bank, N.A. and a syndicate of banks, which was set to mature on February 28, 2024.

On December 27, 2023, we entered into an agreement regarding our 2021 Credit Agreement with the Agent providing that upon closing of the sale of our California Medicare Advantage business, and payments of $274.6 million to the Agent and $24.1 million to the issuers of letters of credit outstanding under the 2021 Credit Agreement, all liabilities of the Company under the 2021 Credit Agreement would be terminated (other than those under the outstanding letters of credit that remained outstanding thereafter) (collectively, the "Termination"). These amounts were paid on January 2, 2024, and on that date the Termination occurred and we had no outstanding borrowings under the 2021 Credit Agreement.

For the six months ended June 30, 2024, upon occurrence of the Termination, we recognized a gain on troubled debt restructuring of $30.3 million. For the six months ended June 30, 2024, the gain on troubled debt restructuring resulted in a decrease of basic and diluted loss per share of $3.71. For the six months ended June 30, 2025, there was no gain on troubled debt restructuring.

As of June 30, 2025 and December 31, 2024, we had undrawn letters of credit of $14.4 million and $16.5 million, respectively.

See subsequent paragraph "Centrum Promissory Note and P-Units" for information describing the $1.0 million of current maturities of long-term borrowings included within short-term borrowings on the Condensed Consolidated Balance Sheets.

**Long-term Borrowings:** 

The balances of the Company's long-term borrowing arrangements, and their related details and components of supplemental cash flow information and non-cash operating and financing activity, consist of the following as of June 30, 2025 and December 31, 2024, and for the six months ended June 30, 2025 and June 30, 2024 *(in thousands)*:

------

<u>[**Table of Contents**](#i3110ff974c884b0fab8eec36c8e490a0_7)</u>

**NeueHealth, Inc.**

**Notes to Condensed Consolidated Financial Statements**

**(Unaudited)**

---

| | | | | | |
|:---|:---|:---|:---|:---|:---|
| | **June 30, 2025** | **June 30, 2025** | **June 30, 2025** | **June 30, 2025** | **June 30, 2025** |
| | | | **Unamortized** | **Unamortized** | |
| **Credit Facilities** | Term Principal | Accrued PIK Principal Additions | Debt Discounts<sup>(3)</sup> | Debt Issuance Costs<sup>(3)</sup> | Current Maturities |
| 2023 Credit Agreement | $96400 | $25220 | $(5762) | $— | $— |
| Hercules Credit Agreement | 30000 | 727 | (947) | (3155) |  |
| Centrum Promissory Note | 63950 |  |  |  |  |
| Centrum P-units | 7000 |  |  |  | (1000) |
|  | 197350 |  |  |  |  |
| &nbsp;&nbsp;Add: |  |  |  |  |  |
| Paid-in-kind interest |  | 25947 |  |  |  |
| &nbsp;&nbsp;Less: |  |  |  |  |  |
| Unamortized debt discount - warrants |  |  | (6709) |  |  |
| Unamortized debt issuance costs |  |  |  | (3155) |  |
| Current maturities of long-term borrowings <sup>(2)</sup> |  |  |  |  | (1000) |
| &nbsp;&nbsp;&nbsp;&nbsp;Total long-term borrowings |  |  |  |  | $**212433** |

---

---

| | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|
| | **Six Months Ended June 30, 2025** | **Six Months Ended June 30, 2025** | **Six Months Ended June 30, 2025** | **Six Months Ended June 30, 2025** | **Six Months Ended June 30, 2025** | **Six Months Ended June 30, 2025** |
| | Annual Interest | Annual Interest | Amortization Expense | Amortization Expense | | |
| **Credit Facilities** | Nominal Rate | Effective Rate | Debt Discounts<sup>(1)</sup> | Debt Issuance Costs<sup>(1)</sup> | Cash Paid for Interest | Maturity Date |
| 2023 Credit Agreement | 15.0% | 16.6% | $406 | $— | $— | 08/2028 |
| Hercules Credit Agreement | 9.7% | 18.7% | $107 | $358 | $1488 | 06/2028 |
| Centrum Promissory Note | 6.0% | 6.0% | $— | $— | $1903 | 10/2028 |
| Centrum P-Units | 6.0% | 6.0% | $— | $— | $236 | 10/2028 |

---

---

| | | | | | |
|:---|:---|:---|:---|:---|:---|
| | **December 31, 2024** | **December 31, 2024** | **December 31, 2024** | **December 31, 2024** | **December 31, 2024** |
| | | | **Unamortized** | **Unamortized** | |
| **Credit Facilities** | Term Principal | Accrued PIK Principal Additions | Debt Discounts<sup>(3)</sup> | Debt Issuance Costs<sup>(3)</sup> | Current Maturities |
| 2023 Credit Agreement | $96400 | $16658 | $(6168) | $— | $— |
| Hercules Credit Agreement | 30000 | 341 | (1055) | (3512) |  |
| Centrum Promissory Note | 63950 |  |  |  |  |
| Centrum P-Units | 8000 |  |  |  | (2000) |
|  | 198350 |  |  |  |  |
| &nbsp;&nbsp;Add: |  |  |  |  |  |
| Paid-in-kind interest |  | 16999 |  |  |  |
| &nbsp;&nbsp;Less: |  |  |  |  |  |
| Unamortized debt discount - warrants |  |  | (7223) |  |  |
| Unamortized debt issuance costs |  |  |  | (3512) |  |
| Current maturities of long-term borrowings <sup>(2)</sup> |  |  |  |  | (2000) |
| &nbsp;&nbsp;&nbsp;&nbsp;Total long-term borrowings |  |  |  |  | $202614 |

---

------

<u>[**Table of Contents**](#i3110ff974c884b0fab8eec36c8e490a0_7)</u>

**NeueHealth, Inc.**

**Notes to Condensed Consolidated Financial Statements**

**(Unaudited)**

---

| | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|
| | **Six Months Ended June 30, 2024** | **Six Months Ended June 30, 2024** | **Six Months Ended June 30, 2024** | **Six Months Ended June 30, 2024** | **Six Months Ended June 30, 2024** | **Six Months Ended June 30, 2024** |
| | Annual Interest | Annual Interest | Amortization Expense | Amortization Expense | | |
| **Credit Facilities** | Nominal Rate | Effective Rate | Debt Discounts<sup>(1)</sup> | Debt Issuance Costs<sup>(1)</sup> | Cash Paid for Interest | Maturity Date |
| 2021 Credit Agreement | 5.0% | 10.1% | $— | $— | $999 | 01/2024 |
| 2023 Credit Agreement | 15.0% | 16.1% | $498 | $— | $2377 | 08/2028 |
| Hercules Credit Agreement | 9.7% | 17.0% | $5 | $17 | $— | 05/2028 |

---

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<sup>(1)</sup> The amortization expenses are presented in interest expense within the Condensed Consolidated Statements of Income (Loss)*.*

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<sup>(2)</sup> The current maturities are presented in short-term borrowings within the Condensed Consolidated Balance Sheets.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<sup>(3)</sup> The unamortized debt discounts and debt issuance costs are presented as a direct deduction from the carrying amount of the respective debt instrument on the balance sheet. These are amortized over the term of the respective credit agreements using the effective interest rate method.

The Company's future annual principal maturities of borrowing arrangements for the remainder of 2025 and for each of the next five full years ending December 31 is as follows *(in thousands)*:

---

| | | | | | |
|:---|:---|:---|:---|:---|:---|
| | **2023 Credit Agreement** | **Hercules Credit Agreement** | **Centrum <br>Promissory Note** | **Centrum <br>P-Units** | **Total** |
| 2025, remainder of | $— | $— | $— | $1000 | $1000 |
| 2026 |  |  |  |  |  |
| 2027 |  |  |  |  |  |
| 2028 | 96400 | 30000 | 63950 | 6000 | 196350 |
| 2029 |  |  |  |  |  |
| 2030 |  |  |  |  |  |
| Thereafter |  |  |  |  |  |
| Total | 96400 | 30000 | 63950 | 7000 | 197350 |

---

***2023 Credit Agreement:*** On August 4, 2023, the Company entered into a credit agreement (as amended, supplemented, restated or otherwise modified from time to time, the "2023 Credit Agreement"), among the Company, NEA 18 Venture Growth Equity, L.P. ("NEA") and the lenders from time to time party thereto (together with NEA and each of their respective successors and assignors, the "Lenders"), to provide for a credit facility pursuant to which, among other things, the lenders provided $60.0 million delayed draw term loan commitments, which are nonconvertible and initially matured on December 31, 2025.

On October 2, 2023, the Company, NEA, as the existing lender (the "Existing Lender"), and California State Teachers' Retirement System, as an incremental lender ("the New Lender") entered into an amendment ("Incremental Amendment No. 1") to the 2023 Credit Agreement to provide for a term loan commitment increase in an aggregate principal amount of $6.4 million by the New Lender under the 2023 Credit Agreement. Loans under Incremental Amendment No. 1 have the same terms as loans under the original term loan commitments provided by the Existing Lender.

On April 8, 2024, the Company and NEA 18 Venture Growth Equity, L.P., New Enterprise Associates 17, L.P., New Enterprise Associates 16, L.P. and New Enterprise Associates 15, L.P. (collectively, the "NEA Lenders") entered into an amendment ("Incremental Amendment No. 2") to the 2023 Credit Agreement to provide for a term loan commitment increase in an

------

<u>[**Table of Contents**](#i3110ff974c884b0fab8eec36c8e490a0_7)</u>

**NeueHealth, Inc.**

**Notes to Condensed Consolidated Financial Statements**

**(Unaudited)**

aggregate principal amount of up to $30.0 million by the NEA Lenders. Loans under Incremental Amendment No. 2 have the same terms as loans under the original term loan commitments provided by the NEA Lenders.

On June 21, 2024, in conjunction with closing on the Hercules Credit Agreement, the Company entered into an amendment ("Amendment No. 3") to the 2023 Credit Agreement to modify the maturity date of the 2023 Credit Agreement to be August 31, 2028, 91 days subsequent to the maturity of the Hercules Credit Agreement.

As we drew on the increased term loan commitment of the 2023 Credit Agreement, in conjunction with the execution of the 2024 NEA Warrantholders Agreement a warrant asset was established for all the warrants available to be issued at the fair value of the warrants on the close date of $6.8 million; upon issuing warrants the corresponding portion of the asset will be recorded as a discount on the term loan and amortized over the remaining term of the debt. The warrant asset is presented in prepaids and other current assets on the Consolidated Balance Sheets. With the issuance of warrants in conjunction with our draws on the 2023 Credit Agreement, the total $6.8 million balance of the warrant asset was recorded as a discount on debt and as of June 30, 2025 and December 31, 2024, there was no warrant asset related to the 2023 Credit Agreement.

We elected to satisfy interest payments through the issuance of additional debt with quarterly paid-in-kind ("PIK") interest payments. As of June 30, 2025, there are no covenant violations or instances of default. The 2023 Credit Agreement does not have a lien against assets of the Company and its subsidiaries.

***Hercules Credit Agreement:*** On June 21, 2024, the Company entered into a loan and security agreement (the "Hercules Credit Agreement"), among the Company, Hercules Capital, Inc. ("Hercules") and the other parties thereto to provide for a credit facility pursuant to which, among other things, Hercules has provided up to four tranches of term loans in an aggregate principal amount of $150.0 million, which mature on June 1, 2028. The four tranches are as follows:

*Tranche 1:* $30,000,000 term loan at closing on June 21, 2024.

*Tranche 2:* up to $25,000,000 term loan was available from November 10 – December 31, 2024 subject to the following conditions: (i) the Company achieved the "Consolidation Condition" or the "2025 Stars Condition" (each as defined in the Hercules Credit Agreement), and (ii) the absence of a material adjustment to the expected payment amount of the "Consolidation and Adjustment Escrow Amount" after giving effect to the "CHP Enrollee Adjustment", if any (each as defined in the Hercules Credit Agreement); in each case, as approved by Hercules in its reasonable discretion.

*Tranche 3:* up to $45,000,000 term loan, plus the undrawn Tranche 2 commitment, if any, that will be available from February 15 – September 15, 2025 subject to the following conditions: (i) the Company has satisfied in full the "CMS Settlement" and the "ACO REACH Deficit Obligation" (each as defined in the Hercules Credit Agreement), and (ii) after the draw down in full of the available "Tranche 3 Advances", the loan parties maintain "Qualified Cash" (as defined in the Hercules Credit Agreement) in an amount greater than or equal to $22,500,000; in each case as approved by Hercules in its reasonable discretion.

*Tranche 4:* up to $50,000,000 term loan, plus the aggregate sum of the undrawn previous commitments, if any, that was available from June 21, 2024 and ending on June 1, 2027, upon further approval by Hercules' investment committee.

As the debt was issued on the Hercules Credit Agreement, in conjunction with the concurrent warrantholders agreements entered into on the close date, a warrant asset was established for all the warrants available to be issued at the fair value of the warrants on the close date of $6.4 million; upon issuing warrants the corresponding portion of the asset will be recorded as a discount on the term loan and amortized over the remaining term of the debt. The warrant asset is presented in prepaids and other current assets on the Consolidated Balance Sheets. With the issuance of warrants in conjunction with our draw of the first tranche, $1.2 million of the warrant asset was recorded as a discount on debt. As of June 30, 2025 and December 31, 2024, the warrant asset related to the Hercules Credit Agreement was $5.3 million.

As of June 30, 2025, under the Hercules Credit Agreement we had $120.0 million of unused borrowing commitments bearing no charge. We elected to satisfy a portion of interest payments through the issuance of additional debt with monthly PIK interest payments bearing a cash interest rate of 2.5% per annum. As of June 30, 2025, there are no covenant violations or

------

<u>[**Table of Contents**](#i3110ff974c884b0fab8eec36c8e490a0_7)</u>

**NeueHealth, Inc.**

**Notes to Condensed Consolidated Financial Statements**

**(Unaudited)**

instances of default. The Hercules Credit Agreement is secured by first priority liens on substantially all assets of the Company and its subsidiaries.

***Centrum Promissory Note and P-Units:*** On October 29, 2024, NeueHealth entered into an Agreement with RRD Healthcare, LLC ("RRD") pursuant to which the Company purchased RRD's remaining 25% equity interest in Centrum Medical Holdings, LLC ("Centrum"). In connection with the transaction, the Company issued a secured promissory note ("Centrum Promissory Note") to RRD in a principal amount of $64.0 million bearing a cash interest rate of 6% per annum, payable monthly. It is due on October 29, 2028 and all or any portion may be prepaid at any time without penalty or premium. As part of the transaction, NeueHealth agreed to pay the former holders of the RRD profit-sharing awards ("P-Unit Awards"), on behalf of RRD, $2.0 million due in 2025, $1.0 million of current maturities remaining due after June 30, 2025, and another $6.0 million due in 2028 in return for the cancellation of the P-Unit Awards; see Note 8, *Commitments and Contingencies* for further information on the transaction and treatment of the P-unit Awards. The P-Unit Awards bear a cash interest rate of 6% per annum, starting on the transaction date, payable quarterly.

As of June 30, 2025, there are no covenant violations or instances of default. The Centrum Promissory Note is secured by second priority liens on substantially all assets of the Company and its subsidiaries.

**Common Stock Warrants:**

***2023 Warrantholders Agreement:*** On August 4, 2023, we entered into a warrantholders agreement (the "NEA Warrantholders Agreement") with NEA 18 Venture Growth Equity, L.P. and the lenders from time-to-time party thereto, setting forth the rights and obligations of the Company and the lenders as holders of the warrants to acquire shares of Common Stock at an exercise price of $0.01 per share, and providing for the issuance of warrants. We established a warrant liability of $25.1 million on this date, representing the 1.7 million warrants available to be issued under the NEA Warrantholders Agreement at a fair market value of $15.12 (closing share price on August 4th, 2023 minus the $0.01 exercise price); the warrant liability is reported on our Condensed Consolidated Balance Sheets. The warrants do not contain any exercise contingencies and expire on the fifth anniversary of the first closing date.

On October 2, 2023, we entered into a warrantholders agreement (the "CalSTRS Warrantholders Agreement" and together with the "NEA Warrantholders Agreement," the "2023 Warrantholders Agreements") with the New Lender, setting forth the rights and obligations of the Company and the lenders as holders of the warrants to acquire shares of Common Stock at an exercise price of $0.01 per share, and providing for the issuance of warrants. We increased the warrant liability by $1.0 million on this date, representing the 0.2 million warrants available to be issued under the CalSTRS Warrantholders Agreement at a fair market value of $5.80 (closing share price on October 2, 2023 minus the $0.01 exercise price). The warrants do not contain any exercise contingencies and expire on the fifth anniversary of the first closing date.

***2024 NEA Warrantholders Agreement:*** On April 8, 2024, the Company and the NEA Lenders entered into a warrantholders agreement ("2024 NEA Warrantholders Agreement") setting forth the rights and obligations of the Company and the NEA Lenders as holders of the warrants to acquire shares of Common Stock at an exercise price of $0.01 per share, and providing for the issuance of warrants. Warrants under the 2024 NEA Warrantholders Agreement have the same terms as warrants issued under the original Warrantholders Agreement executed on August 4, 2023. We established a warrant liability of $6.8 million on this date, representing the 1.1 million warrants available to be issued under the 2024 NEA Warrantholders Agreement at a fair market value of $6.14 (closing share price on April 8, 2024 minus the $0.01 exercise price); the warrant liability is reported on our Condensed Consolidated Balance Sheets. The warrants do not contain any exercise contingencies and expire five years from the date the initial warrants are issued under the 2024 NEA Warrantholders Agreement.

***Hercules Warrantholders Agreements***: On June 21, 2024, the Company entered into warrantholders agreements (the "Hercules Warrantholders Agreements") with Hercules and the lenders from time-to-time party to the Hercules Credit Agreement, setting forth the rights and obligations of the Company and the lenders as holders of the warrants to acquire an aggregate of 1.3 million shares of Common Stock at an exercise price of $0.01 per share, and providing for the issuance of warrants. The warrants may be settled with cash or net settlement in shares at the determination of the warrantholders. We established a warrant liability of $6.4 million on this date, representing the 1.3 million warrants available to be issued under the Hercules Warrantholders Agreements at a fair market value of $5.14 (closing share price on June 21, 2024 minus the $0.01 exercise price); the warrant liability is reported on our Condensed Consolidated Balance Sheets. The warrants do not contain any exercise contingencies and expire on the seventh anniversary of the closing date.

------

<u>[**Table of Contents**](#i3110ff974c884b0fab8eec36c8e490a0_7)</u>

**NeueHealth, Inc.**

**Notes to Condensed Consolidated Financial Statements**

**(Unaudited)**

The following table shows the warrant liability as of June 30, 2025 and 2024, and the components of the change in warrant liability for the six months then ended, respectively (*in thousands*):

---

| | | |
|:---|:---|:---|
| | **2025** | **2024** |
| Balance at January 1, | $29738 | $13971 |
| Newly executed Warrantholders Agreement |  | 13262 |
| Antidilutive issuances <sup>(1)</sup> |  | 212 |
| Change in fair value of outstanding warrants | (2087) | (4496) |
| Warrants issued and classified as equity instruments |  | (1157) |
| Balance at June 30, | $27651 | $21792 |

---

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<sup>(1)</sup> The 2023 Warrantholders Agreement and 2024 NEA Warrantholders Agreement contain a Dilutive Issuance provision providing that the number of shares issuable under outstanding warrants be increased upon issuance by the Company of shares of common stock (or the issuance of securities convertible into, or exchangeable for, shares of common stock) for a market price lower than that of August 29, 2023, in the case of the 2023 Warrantholders Agreement, and April 30, 2024, in the case of the 2024 NEA Warrantholders Agreement. For the period ended December 31, 2024 the number of shares issuable under the warrants issued under the 2023 Warrantholders Agreement and 2024 NEA Warrantholders Agreement were increased by 41,158. The warrants were granted at a fair market value of $5.14 (closing share price on June 21, 2024 minus the $0.01 exercise price).

For the three months ended June 30, 2025 and 2024, we had net warrant expense of $0.6 million and net warrant income of $2.2 million. For the six months ended June 30, 2025 and 2024, we had net warrant income of $2.1 million and $4.3 million, respectively.

As of June 30, 2025 no issued warrants have been exercised. The table below summarizes the number of warrants that remain available to be issued under each of the Warrantholders Agreements as of June 30, 2025:

---

| | |
|:---|:---|
| 2023 Warrantholders Agreement |  |
| 2024 NEA Warrantholders Agreement |  |
| Hercules Warrantholders Agreements | 1,025,000 |

---

The Company classifies its warrant liability as Level 2 fair value because they are valued using observable, unadjusted quoted prices in active markets. See Note 14, *Discontinued Operations* for the full definition of Level 1, Level 2, and Level 3 fair values.

**NOTE 5. SHARE-BASED COMPENSATION**

***2016 Incentive Plan***

The Company adopted its 2016 Stock Incentive Plan (the "2016 Incentive Plan") in March 2016. The 2016 Incentive Plan allowed for the Company to grant stock options, restricted stock awards ("RSAs"), and restricted stock units ("RSUs") to certain employees, consultants and non-employee directors. The 2016 Incentive Plan was initially adopted on March 25, 2016, and most recently amended in December 2020. Following the effectiveness of our 2021 Omnibus Plan (the "2021 Incentive Plan"), no further awards will be granted under the 2016 Incentive Plan. However, all outstanding awards granted under the 2016 Incentive Plan will continue to be governed by the existing terms of the 2016 Incentive Plan and the applicable award agreements.

***2021 Incentive Plan***

The 2021 Incentive Plan was adopted by our Board of Directors on May 21, 2021 and approved by our stockholders on May 25, 2021 and June 5, 2021. The 2021 Incentive Plan allows the Company to grant stock options, RSAs, RSUs, stock appreciation

------

<u>[**Table of Contents**](#i3110ff974c884b0fab8eec36c8e490a0_7)</u>

**NeueHealth, Inc.**

**Notes to Condensed Consolidated Financial Statements**

**(Unaudited)**

rights, other equity-based awards, and cash-based incentive awards to certain employees, consultants and non-employee directors. The 2021 Incentive Plan was most recently amended in May 2024. As of June 30, 2025 there are 4.4 million shares of common stock authorized for issuance under the 2021 Incentive Plan and a total of 0.9 million shares of common stock were available for future issuance under the 2021 Incentive Plan.

***Share-Based Compensation Expense***

We recognized share-based compensation expense of $7.5 million and $39.9 million for the six months ended June 30, 2025 and 2024, respectively, which is included in operating costs in the Condensed Consolidated Statements of Income (Loss).

***Stock Options***

The Board of Directors, or the Compensation and Human Capital Committee of the Board of Directors, as applicable, determines the exercise price, vesting periods and expiration date at the time of the grant. Stock options granted after the beginning of the third quarter of 2021 generally vest ratably over three years. Option grants generally expire 10 years from the date of grant.&nbsp;&nbsp;&nbsp;&nbsp;

There were no options granted during the six months ended June 30, 2025.

The activity for stock options for the six months ended June 30, 2025 is as follows *(in thousands, except exercise price, weighted average contractual life, and aggregate intrinsic value)*:

---

| | | | | |
|:---|:---|:---|:---|:---|
| | **Shares** | **Weighted Average<br>Exercise Price** | **Weighted Average<br>Remaining<br>Contractual Life<br>(In Years)** | **Aggregate <br>Intrinsic Value** |
| Outstanding at January 1, 2025 | 423 | $139.33 | 5.2 | $205 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Granted |  |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Exercised |  |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Forfeited |  |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Expired | (5) | 151.51 |  |  |
| Outstanding at June 30, 2025 | 418 | $139.14 | 4.8 | $— |

---

We recognized share-based compensation expense related to stock options of $2.9 million for the six months ended June 30, 2025, which is included in operating costs in the Condensed Consolidated Statements of Income (Loss). At June 30, 2025, there was no unrecognized compensation expense related to stock options.

***Restricted Stock Units***

RSUs represent the right to receive shares of our common stock at a specified date in the future and generally vest over a three-year period, except for Board of Director grants which generally vest one year from the date of grant. The fair value of RSUs is determined based on the closing market price of our common stock on the date of grant.

------

<u>[**Table of Contents**](#i3110ff974c884b0fab8eec36c8e490a0_7)</u>

**NeueHealth, Inc.**

**Notes to Condensed Consolidated Financial Statements**

**(Unaudited)**

The following table summarizes RSU award activity for the six months ended June 30, 2025 *(in thousands, except weighted average grant date fair value)*:

---

| | | |
|:---|:---|:---|
| | **Number of RSUs** | **Weighted Average Grant Date Fair Value** |
| Unvested RSUs at January 1, 2025 | 2871 | $11.08 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Granted |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Vested | (703) | 23.80 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Forfeited | (39) | 8.29 |
| Unvested RSUs at June 30, 2025 | 2129 | $6.92 |

---

We recognized share-based compensation expense related to RSUs of $4.6 million for the six months ended June 30, 2025, which is included in operating costs in the Condensed Consolidated Statements of Income (Loss). As of June 30, 2025, there was $7.8 million of unrecognized compensation expense related to the RSU grants, which is expected to be recognized over a weighted-average period of 1.3 years.

***Performance-based Restricted Stock Units ("PSUs")***

In connection with our initial public offering, our Board of Directors approved the grant of PSUs to members of our executive leadership team. The grant encompassed a total of 183,750 PSUs, separated into four equal tranches, each of which are eligible to vest based on the achievement of predetermined stock price goals and a minimum service period of 3.0 years. The fair value of the PSUs was determined using a Monte-Carlo simulation.

The following table summarizes PSU award activity for the six months ended June 30, 2025 *(in thousands, except weighted average grant date fair value)*:

---

| | | |
|:---|:---|:---|
| | **Number of PSUs** | **Weighted Average Grant Date Fair Value** |
| Unvested PSUs at January 1, 2025 | 105 | $744.00 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Granted |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Forfeited | (13) | 744.02 |
| Unvested PSUs at June 30, 2025 | 92 | $744.00 |

---

We recognized no share-based compensation expense related to PSUs for the six months ended June 30, 2025. At June 30, 2025, there was no unrecognized compensation expense related to the PSU grant as the minimum service period was achieved in June 2024. The PSUs will expire in June 2026 if the predetermined stock price goals are not achieved.

***Liability Classified Share-based Award***

In May 2024, the Company granted share-based awards to certain employees. These awards provided the option for settlement in either cash or shares, at the discretion of the Company. In January 2025, the Compensation and Human Capital Committee of the Board of Directors approved the settlement of the employee portion of the award in cash at 100% of target. The same approval was received in April 2025 for the Board portion of the award. The payment of the employee portion of the award occurred in March 2025 and the payment of the Board portion of the award occurred in May 2025.

These awards were initially measured at fair value on the grant date and subsequently remeasured at each reporting date until settlement. The remeasurement of the liability at each reporting date impacts the Company's financial statements through adjustments to share-based compensation expense. The liability was derecognized upon settlement, with any difference between the final settlement amount and the remeasured liability amount recognized in the income statement. The fair value of the liability-classified awards is derived from the targeted bonus amount, which represents the expected payout if performance

------

<u>[**Table of Contents**](#i3110ff974c884b0fab8eec36c8e490a0_7)</u>

**NeueHealth, Inc.**

**Notes to Condensed Consolidated Financial Statements**

**(Unaudited)**

targets are met. This amount is adjusted for estimated forfeitures to account for the probability that some awards will not vest due to employee turnover or failure to meet performance criteria.

The following table provides a reconciliation of the beginning and ending balances of the share-based payment liability *(in thousands)*:

---

| | |
|:---|:---|
| | **Fair Value** |
| Balance at January 1, 2025 | $6402 |
| Changes in fair value (forfeitures) | (41) |
| Payments | (6361) |
| Balance at June 30, 2025 | $— |

---

As of June 30, 2025 and December 31, 2024, the liability for these awards was remeasured at fair value, resulting in a recognized liability of $0.0 million and $6.4 million, respectively. The changes in fair value of the liability were recognized as operating costs in the Condensed Consolidated Statements of Comprehensive Income (Loss). The total expense recognized for these liability-classified awards for the three and six months ended June 30, 2025 was immaterial. The liability for these awards is included within other current liabilities on the Condensed Consolidated Balance Sheets.

As of June 30, 2025 there is no unrecognized expense of the liability classified share-based award.

**NOTE 6. REDEEMABLE CONVERTIBLE PREFERRED STOCK**

Pursuant to the Certificate of Designations designating the shares of our Series A Convertible Perpetual Preferred Stock and the Certificate of Designations designating the shares of our Series B Convertible Perpetual Preferred Stock (collectively, the "Preferred Stock") each of which we filed with the Secretary of State of the State of Delaware (together, the "Certificate of Designations"), the Preferred Stock ranks senior to our shares of common stock with respect to dividend rights and rights on the distribution of assets on any voluntary or involuntary liquidation, dissolution or winding up of the affairs of the Company. The Preferred Stock is convertible into common stock and is entitled to an initial liquidation preference, in each case subject to certain limitations outlined in the Certificates of Designations.

**Series A Convertible Preferred Stock**

On January 3, 2022, we issued 750,000 shares of Series A Preferred Stock, par value $0.0001 per share, for an aggregate purchase price of $750.0 million, or $1,000 per share.

The Series A Preferred Stock ranks senior to the shares of the Company's common stock with respect to dividend rights and rights on the distribution of assets on any voluntary or involuntary liquidation, dissolution or winding up of the affairs of the Company. The Preferred Stock has an initial liquidation preference of $1,000 per share, which shall increase by accumulated quarterly dividends that are not paid in cash ("compounded dividends"). Holders of the Series A Preferred Stock are entitled to a dividend at the rate of 5.0% per annum, accruing daily and payable quarterly in arrears and subject to certain adjustments, as set forth in the Certificate of Designations. Dividends will be payable in cash, by increasing the amount of liquidation preference (compounded dividends) with respect to a share of Series A Preferred Stock, or any combination thereof, at the sole discretion of the Company. The Series A Preferred Stock had accrued compounded dividends of $141.9 million and $120.2 million as of June 30, 2025 and December 31, 2024, respectively.

The Series A Preferred Stock will be convertible at the option of the holders into (I) the number of shares of common stock equal to the quotient of (a) the sum of (x) the liquidation preference (reflecting increases for compounded dividends) plus (y) the accrued dividends with respect to each share of Series A Preferred Stock as of the applicable conversion date divided by (b) the conversion price (initially approximately $364.00 per share and approximately $260.34 per share subsequent to the issuance of all warrants prior to the six months ended June 30, 2025) as of the applicable conversion date plus (II) cash in lieu of fractional shares, subject to certain anti-dilution adjustments. At any time after January 3, 2025, if the closing price per share of Common Stock on the New York Stock Exchange was greater than 175% of the then effective Conversion Price for (x) each of at least twenty (20) trading days in any period of thirty (30) consecutive trading days and (y) the last trading day immediately

------

<u>[**Table of Contents**](#i3110ff974c884b0fab8eec36c8e490a0_7)</u>

**NeueHealth, Inc.**

**Notes to Condensed Consolidated Financial Statements**

**(Unaudited)**

before the Company provides the holders with notice of its election to convert all of the Series A Preferred Stock into the relevant number of shares of common stock, the Company may elect to convert all of the Series A Preferred Stock into the relevant number of shares of common stock.

Under the Certificate of Designations, holders of the Series A Preferred Stock are entitled to vote with the holders of the common stock on an as-converted basis, solely with respect to (i) a change of control transaction (to the extent such change of control transaction is submitted to a vote of the holders of the common stock) or (ii) the issuance of capital stock by the Company in connection with an acquisition by the Company (to the extent such issuance is submitted to a vote of the holders of the common stock), subject to certain restrictions. Holders of the Series A Preferred Stock are entitled to a separate class vote with respect to, among other things, amendments to the Company's organizational documents that have an adverse effect on the Series A Preferred Stock, authorizations or issuances by the Company of securities that are senior to the Series A Preferred Stock, increases or decreases in the number of authorized shares of Preferred Stock, and issuances of shares of the Series A Preferred Stock after January 3, 2022.

At any time following January 3, 2027, the Company may redeem all of the Series A Preferred Stock for a per share amount in cash equal to: (i) the sum of (A) the liquidation preference (reflecting increases for compounded dividends) thereof plus (B) all accrued dividends as of the applicable redemption date, multiplied by (ii) (A) 105% if the redemption occurs at any time prior to January 3, 2029 and (B) 100% if the redemption occurs at any time on or after January 3, 2029. Upon certain change of control events involving the Company, the holders of the Series A Preferred Stock may, at such holder's election, convert their shares of Series A Preferred Stock into common stock at the then-current conversion price or require the Company to purchase all or a portion of such holder's shares of Preferred Stock that have not been so converted at a purchase price per share of Preferred Stock, payable in cash, equal to the greater of (I) (A) if the change of control effective date occurs at any time prior to January 3, 2029, the product of 105% multiplied by the sum of (x) the liquidation preference of such share of Series A Preferred Stock (reflecting increases for compounded dividends) plus (y) the accrued dividends in respect of such share of Series A Preferred Stock as of the change of control purchase date and (B) if the change of control effective date occurs on or after January 3, 2029, the sum of (x) the liquidation preference (reflecting increases for compounded dividends) of such share of Series A Preferred Stock plus (y) the accrued dividends in respect of such share of Series A Preferred Stock as of the change of control purchase date and (II) the consideration that would have been payable in connection with such change of control if such share of Series A Preferred Stock had been converted into Common Stock immediately prior to the change of control.

**Series B Convertible Preferred Stock**

On October 17, 2022, we issued 175,000 shares of Series B Preferred Stock, par value $0.0001 per share, for an aggregate purchase price of $175.0 million, or $1,000 per share.

The Series B Preferred Stock ranks senior to the shares of the Company's common stock with respect to dividend rights and rights on the distribution of assets on any voluntary or involuntary liquidation, dissolution or winding up of the affairs of the Company. The Preferred Stock has an initial liquidation preference of $1,000 per share, which shall increase by compounded dividends. Holders of the Series B Preferred Stock are entitled to a dividend at the rate of 5.0% per annum, accruing daily and payable quarterly in arrears and subject to certain adjustments, as set forth in the Certificate of Designations. Dividends will be payable in cash, by increasing the amount of liquidation preference (compounded dividends) with respect to a share of Series B Preferred Stock, or any combination thereof, at the sole discretion of the Company. The Series B Preferred Stock had accrued compounded dividends of $25.1 million and $20.3 million as of June 30, 2025 and December 31, 2024, respectively.

The Series B Preferred Stock will be convertible at the option of the holders into (I) the number of shares of common stock equal to the quotient of (a) the sum of (x) the liquidation preference (reflecting increases for compounded dividends) plus (y) the accrued dividends with respect to each share of Series B Preferred Stock as of the applicable conversion date divided by (b) the conversion price (initially approximately $113.60 per share and approximately $90.72 per share subsequent to the issuance of all warrants prior to the six months ended June 30, 2025) as of the applicable conversion date plus (II) cash in lieu of fractional shares, subject to certain anti-dilution adjustments. At any time after October 17, 2025, if the closing price per share of common stock on the NYSE was greater than 287% of the then effective Conversion Price for (x) each of at least twenty (20) trading days in any period of thirty (30) consecutive trading days and (y) the last trading day immediately before the Company provides the holders with notice of its election to convert all of the Series B Preferred Stock into the relevant number of shares

------

<u>[**Table of Contents**](#i3110ff974c884b0fab8eec36c8e490a0_7)</u>

**NeueHealth, Inc.**

**Notes to Condensed Consolidated Financial Statements**

**(Unaudited)**

of common stock, the Company may elect to convert all of the Series B Preferred Stock into the relevant number of shares of common stock.

Under the Certificate of Designations, holders of the Series B Preferred Stock are entitled to vote with the holders of the common stock on an as-converted basis, solely with respect to (i) a change of control transaction (to the extent such change of control transaction is submitted to a vote of the holders of the common stock) or (ii) the issuance of capital stock by the Company in connection with an acquisition by the Company (to the extent such issuance is submitted to a vote of the holders of the common stock), subject to certain restrictions. Holders of the Series B Preferred Stock are entitled to a separate class vote with respect to, among other things, amendments to the Company's organizational documents that have an adverse effect on the Series B Preferred Stock, authorizations or issuances by the Company of securities that are senior to the Series B Preferred Stock, increases or decreases in the number of authorized shares of Preferred Stock, and issuances of shares of the Series B Preferred Stock after October 17, 2022.

At any time following October 17, 2027, the Company may redeem all of the Series B Preferred Stock for a per share amount in cash equal to: (i) the sum of (A) the liquidation preference (reflecting increases for compounded dividends) thereof plus (B) all accrued dividends as of the applicable redemption date, multiplied by (ii) (A) 105% if the redemption occurs at any time prior to October 17, 2029 and (B) 100% if the redemption occurs at any time on or after October 17, 2029. Upon certain change of control events involving the Company, the holders of the Series B Preferred Stock may, at such holder's election, convert their shares of Series B Preferred Stock into common stock at the then-current conversion price or require the Company to purchase all or a portion of such holder's shares of Preferred Stock that have not been so converted at a purchase price per share of Preferred Stock, payable in cash, equal to the greater of (I) (A) if the change of control effective date occurs at any time prior to October 17, 2029, the product of 105% multiplied by the sum of (x) the liquidation preference of such share of Series B Preferred Stock (reflecting increases for compounded dividends) plus (y) the accrued dividends in respect of such share of Series B Preferred Stock as of the change of control purchase date and (B) if the change of control effective date occurs on or after October 17, 2029, the sum of (x) the liquidation preference (reflecting increases for compounded dividends) of such share of Series B Preferred Stock plus (y) the accrued dividends in respect of such share of Series B Preferred Stock as of the change of control purchase date and (II) the consideration that would have been payable in connection with such change of control if such share of Series B Preferred Stock had been converted into common stock immediately prior to the change of control.

**NOTE 7. NET LOSS PER SHARE**

The following table sets forth the computation of basic and diluted net loss per share attributable to common stockholders for the three and six months ended June 30 *(in thousands, except for per share amounts)*:

---

| | | | | |
|:---|:---|:---|:---|:---|
| | **Three Months Ended<br>June 30,** | **Three Months Ended<br>June 30,** | **Six Months Ended<br>June 30,** | **Six Months Ended<br>June 30,** |
| | **2025** | **2024** | **2025** | **2024** |
| &nbsp;&nbsp;Loss from continuing operations, net noncontrolling interests and accrued preferred stock dividends | $(15115) | $(52951) | $(30580) | $(71604) |
| &nbsp;&nbsp;Loss from discontinued operations | (8386) | (18439) | (17796) | (28304) |
| Net loss attributable to NeueHealth, Inc. common shareholders | $(23501) | $(71390) | $(48376) | $(99908) |
| Weighted-average number of shares outstanding used to compute net loss per share attributable to common stockholders, basic and diluted | 8978 | 8253 | 8750 | 8166 |
| **Basic and diluted loss per share attributable to NeueHealth, Inc. common shareholders** | **Basic and diluted loss per share attributable to NeueHealth, Inc. common shareholders** | **Basic and diluted loss per share attributable to NeueHealth, Inc. common shareholders** | **Basic and diluted loss per share attributable to NeueHealth, Inc. common shareholders** | **Basic and diluted loss per share attributable to NeueHealth, Inc. common shareholders** |
| &nbsp;&nbsp;Continuing operations | $(1.68) | $(6.42) | $(3.49) | $(8.77) |
| &nbsp;&nbsp;Discontinued operations | $(0.94) | $(2.23) | $(2.04) | $(3.46) |
| Net loss per share attributable to common stockholders, basic and diluted | $(2.62) | $(8.65) | $(5.53) | $(12.23) |

---

------

<u>[**Table of Contents**](#i3110ff974c884b0fab8eec36c8e490a0_7)</u>

**NeueHealth, Inc.**

**Notes to Condensed Consolidated Financial Statements**

**(Unaudited)**

The following outstanding shares of potentially dilutive securities were excluded from the computation of diluted net loss per share because including them would have had an anti-dilutive effect for the three and six months ended June 30 *(in thousands)*:

---

| | | |
|:---|:---|:---|
| | **June 30,** | **June 30,** |
| | **2025** | **2024** |
| Redeemable convertible preferred stock (as converted to common stock) | 5632 | 5241 |
| Issued and outstanding common stock warrants | 3213 | 2842 |
| Stock options to purchase common stock | 418 | 534 |
| Restricted stock units | 2129 | 3045 |
| Total | 11392 | 11662 |

---

**NOTE 8. COMMITMENTS AND CONTINGENCIES**

**Legal proceedings:** In the normal course of business, we could be involved in various legal proceedings such as, but not limited to, the following: litigation concerning ongoing mergers and/or acquisitions, lawsuits alleging negligence in care or general liability, violation of regulatory bodies' rules and regulations, or violation of federal and/or state laws.

On January 6, 2022, a putative securities class action lawsuit was filed against us and certain of our officers and directors in the Eastern District of New York. The case is captioned *Marquez v. Bright Health Group, Inc.* et al., 1:22-cv-00101 (E.D.N.Y.). The lawsuit alleges, among other things, that we made materially false and misleading statements regarding our business, operations, and compliance policies, which in turn adversely affected our stock price. An amended complaint was filed on June 24, 2022, which expands on the allegations in the original complaint and alleges a putative class period of June 24, 2021 through March 1, 2022. The amended complaint also adds as defendants the underwriters of our initial public offering. The Company has served a motion to dismiss the amended complaint. On November 1, 2024, the court issued a memorandum and order and entered judgment granting the motion to dismiss in full. The plaintiff appealed this decision on November 27, 2024.

In connection with the NEA Merger, announced on December 23, 2024, three lawsuits have been filed: two were filed in New York (Williams v. NeueHealth, Inc. et al., No. 652386/2025 (N.Y. Sup. Ct. Apr. 16, 2025); Ballard v. NeueHealth Inc. et al., No. 652405/2025 (N.Y. Sup. Ct. Apr. 17, 2025)) and one was filed in the Circuit Court for the Eleventh Judicial District of Florida (Berger v. Adkins, et al., No. [Unknown], (Fla. 11th Jud. Cir. Ct. Apr. 23, 2025)). Additionally, the Company has received certain disclosure and books and records demands in regard to the transaction.

We intend to vigorously defend the Company in the above actions, but there can be no assurance that we will be successful in any defense.

Based on our assessment of the facts underlying the claims, the degree to which we intend to defend the Company in this matter, if needed, and the court's ruling, the amount or range of reasonably possible losses, if any, cannot be estimated. We have not accrued for any potential loss as of June 30, 2025 and December 31, 2024 for these actions.

**Other commitments:** As of June 30, 2025, we had letters of credit of $14.4 million, as well as surety bonds of $19.5 million. On our Condensed Consolidated Balance Sheets, $24.3 million of the cash and cash equivalents and $13.9 million of the short-term investments is restricted as collateral to our undrawn letters of credit and surety bonds.

**NOTE 9. SEGMENTS AND GEOGRAPHIC INFORMATION**

Factors used to determine our reportable segments include the nature of operating activities, economic characteristics, existence of separate senior management teams and the type of information used by the Company's Chief Executive Officer, the Company's chief operating decision maker ("CODM"), to evaluate its results of operations. We have identified two operating segments within our continuing operations based on our primary product and service offerings: NeueCare and NeueSolutions.

------

<u>[**Table of Contents**](#i3110ff974c884b0fab8eec36c8e490a0_7)</u>

**NeueHealth, Inc.**

**Notes to Condensed Consolidated Financial Statements**

**(Unaudited)**

NeueCare and NeueSolutions, which make up our value-driven Consumer Care business that manages risk in partnership with external payors, aim to significantly reduce the friction and current lack of coordination between payors by delivering on our Fully Aligned Care Model with multiple payors. The following is a description of the types of products and services from which the two reportable segments of our continuing operations derive their revenues:

**NeueCare:** Provides care services in our clinics with wrap around care management and care coordination activities for those members where we take full or partial risk. As of June 30, 2025, NeueCare provides virtual and in-person clinical care through its 67 owned primary care clinics within an integrated care delivery system. Through these risk-bearing clinics and our affiliated network of care providers, our NeueCare segment serves approximately 547,000 consumers, inclusive of 504,000 value-based care consumers and 43,000 fee-for-service consumers. NeueCare customers include external payors, third party administrators, affiliated providers, and direct-to-government programs.

**NeueSolutions:** Our provider enablement business that facilitates care coordination activities through the use of population health tools including technology, data analytics, care and utilization management, and clinical solutions and care teams to support patients. As of June 30, 2025, NeueSolutions has approximately 34,000 value-based care consumers attributed to ACO REACH, 8,000 value-based care consumers attributed to MSSP, and 148,000 enablement services lives, representing members attributed to NeueHealth by provider partner groups that are outside of the NeueHealth owned network.

The Company's accounting policies for reportable segment operations are consistent with those described in Note 2, *Summary of Significant Accounting Policies,* in our 2024 Form 10-K. We utilize operating income (loss) as the profitability metric in assessing performance for our reportable segments. Presented by reportable segment and reconciled to the Consolidated Statements of Income (Loss), the significant segment revenue and expense categories that are regularly provided to and monitored by the CODM, as well as included in the calculation of operating income (loss), are disaggregated in the table below.

------

<u>[**Table of Contents**](#i3110ff974c884b0fab8eec36c8e490a0_7)</u>

**NeueHealth, Inc.**

**Notes to Condensed Consolidated Financial Statements**

**(Unaudited)**

The following tables present the reportable segment financial information for the three and six months ended June 30, 2025 and 2024 *(in thousands)*:

---

| | | | | |
|:---|:---|:---|:---|:---|
| **Three Months Ended June 30, 2025** | **NeueCare** | **NeueSolutions** | **Corporate & Eliminations** | **Consolidated** |
| Capitated revenue | $81407 | $1125 | $— | $82532 |
| ACO REACH revenue |  | 115339 |  | 115339 |
| Service revenue | 6874 | 3546 |  | 10420 |
| Investment income | 120 |  | 671 | 791 |
| &nbsp;&nbsp;Total unaffiliated revenue | 88401 | 120010 | 671 | 209082 |
| Affiliated revenue | 3227 |  | (3227) |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Total segment revenue | 91628 | 120010 | (2556) | 209082 |
| Operating expenses |  |  |  |  |
| &nbsp;&nbsp;Medical costs | 36723 | 112914 | (3227) | 146410 |
| &nbsp;&nbsp;Operating costs |  |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Compensation and fringe | 19599 | 2166 | 7732 | 29497 |
| &nbsp;&nbsp;&nbsp;&nbsp;Professional fees | 3709 | 831 | 255 | 4795 |
| &nbsp;&nbsp;&nbsp;&nbsp;Other administrative | 5628 | 1545 | 3395 | 10568 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Total segment operating costs | 28936 | 4542 | 11382 | 44860 |
| &nbsp;&nbsp;&nbsp;&nbsp;Depreciation and amortization | 2757 |  | 798 | 3555 |
| &nbsp;&nbsp;&nbsp;&nbsp;Intangible asset impairment |  |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Total segment operating expenses | 68416 | 117456 | 8953 | 194825 |
| Operating income (loss) | 23212 | 2554 | (11509) | 14257 |

---

------

<u>[**Table of Contents**](#i3110ff974c884b0fab8eec36c8e490a0_7)</u>

**NeueHealth, Inc.**

**Notes to Condensed Consolidated Financial Statements**

**(Unaudited)**

---

| | | | | |
|:---|:---|:---|:---|:---|
| **Six Months Ended June 30, 2025** | **NeueCare** | **NeueSolutions** | **Corporate & Eliminations** | **Consolidated** |
| Capitated revenue | $162394 | $1125 | $— | $163519 |
| ACO REACH revenue |  | 239379 |  | 239379 |
| Service revenue | 13138 | 7116 |  | 20254 |
| Investment income | 477 |  | 1240 | 1717 |
| &nbsp;&nbsp;Total unaffiliated revenue | 176009 | 247620 | 1240 | 424869 |
| Affiliated revenue | 6136 |  | (6136) |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Total segment revenue | 182145 | 247620 | (4896) | 424869 |
| Operating expenses |  |  |  |  |
| &nbsp;&nbsp;Medical costs | 74241 | 239199 | (6136) | 307304 |
| &nbsp;&nbsp;Operating costs |  |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Compensation and fringe | 37896 | 4312 | 18698 | 60906 |
| &nbsp;&nbsp;&nbsp;&nbsp;Professional fees | 6745 | 1810 | 2934 | 11489 |
| &nbsp;&nbsp;&nbsp;&nbsp;Other administrative | 11505 | 2737 | 6896 | 21138 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Total segment operating costs | 56146 | 8859 | 28528 | 93533 |
| &nbsp;&nbsp;Depreciation and amortization | 5539 |  | 1575 | 7114 |
| &nbsp;&nbsp;Intangible asset impairment |  |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Total segment operating expenses | 135926 | 248058 | 23967 | 407951 |
| Operating income (loss) | 46219 | (438) | (28863) | 16918 |

---

---

| | | | | |
|:---|:---|:---|:---|:---|
| **Three Months Ended June 30, 2024** | **NeueCare** | **NeueSolutions** | **Corporate & Eliminations** | **Consolidated** |
| Capitated revenue | $64005 | $— | $— | $64005 |
| ACO REACH revenue |  | 149802 |  | 149802 |
| Service revenue | 9803 | 2273 |  | 12076 |
| Investment income | 21 |  | 87 | 108 |
| &nbsp;&nbsp;Total unaffiliated revenue | 73829 | 152075 | 87 | 225991 |
| Affiliated revenue | 3156 |  | (3156) |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Total segment revenue | 76985 | 152075 | (3069) | 225991 |
| Operating expenses |  |  |  |  |
| &nbsp;&nbsp;Medical costs | 33579 | 147258 | (3156) | 177681 |
| &nbsp;&nbsp;Operating costs |  |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Compensation and fringe | 22041 | 2173 | 25276 | 49490 |
| &nbsp;&nbsp;&nbsp;&nbsp;Professional fees | 3531 | 515 | 2523 | 6569 |
| &nbsp;&nbsp;&nbsp;&nbsp;Other administrative | 9104 | 1732 | 3575 | 14411 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Total segment operating costs | 34676 | 4420 | 31374 | 70470 |
| &nbsp;&nbsp;&nbsp;&nbsp;Depreciation and amortization | 3221 |  | 757 | 3978 |
| &nbsp;&nbsp;&nbsp;&nbsp;Intangible asset impairment | 11411 |  |  | 11411 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Total segment operating expenses | 82887 | 151678 | 28975 | 263540 |
| Operating (loss) income | (5902) | 397 | (32044) | (37549) |

---

------

<u>[**Table of Contents**](#i3110ff974c884b0fab8eec36c8e490a0_7)</u>

**NeueHealth, Inc.**

**Notes to Condensed Consolidated Financial Statements**

**(Unaudited)**

---

| | | | | |
|:---|:---|:---|:---|:---|
| **Six Months Ended June 30, 2024** | **NeueCare** | **NeueSolutions** | **Corporate & Eliminations** | **Consolidated** |
| Capitated revenue | $125471 | $— | $— | $125471 |
| ACO REACH revenue |  | 321613 |  | 321613 |
| Service revenue | 19333 | 4358 |  | 23691 |
| Investment income | 21 |  | 290 | 311 |
| &nbsp;&nbsp;Total unaffiliated revenue | 144825 | 325971 | 290 | 471086 |
| Affiliated revenue | 5783 |  | (5783) |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Total segment revenue | 150608 | 325971 | (5493) | 471086 |
| Operating expenses |  |  |  |  |
| &nbsp;&nbsp;Medical costs | 61015 | 319323 | (5783) | 374555 |
| &nbsp;&nbsp;Operating costs |  |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Compensation and fringe | 45555 | 4693 | 47319 | 97567 |
| &nbsp;&nbsp;&nbsp;&nbsp;Professional fees | 6297 | 1141 | 5631 | 13069 |
| &nbsp;&nbsp;&nbsp;&nbsp;Other administrative | 15413 | 3349 | 7833 | 26595 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Total segment operating costs | 67265 | 9183 | 60783 | 137231 |
| &nbsp;&nbsp;Depreciation and amortization | 7007 |  | 1533 | 8540 |
| &nbsp;&nbsp;Intangible asset impairment | 11411 |  |  | 11411 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Total segment operating expenses | 146698 | 328506 | 56533 | 531737 |
| Operating income (loss) | 3910 | (2535) | (62026) | (60651) |

---

We do not include asset information by reportable segment in the reporting provided to the CODM.

**NOTE 10. INCOME TAXES** 

Income tax was a benefit of $0.02 million and $0.2 million, for the three months ended June 30, 2025 and 2024, respectively. For the six months ended June 30, 2025 and 2024, income tax was an expense of $0.1 million and $0.5 million, respectively. The impact from income taxes varies from the federal statutory rate of 21.0% due to state income taxes, changes in the valuation allowance for deferred tax assets and adjustments for permanent differences. The expense for both periods largely relates to estimated state income taxes attributable to income earned in separate filing states without state net operating loss carryforwards and in combined filing states that restrict which entities within the group may use specific net operating loss carryforwards.

We assess whether sufficient future taxable income will be generated to permit the use of deferred tax assets. This assessment includes consideration of the cumulative losses incurred over the three-year period ended June 30, 2025. Such objective evidence limits the ability to consider other subjective evidence, such as the Company's projections for future earnings. On the basis of this evaluation, we have recorded a valuation allowance for deferred tax assets to the extent that they cannot be supported by reversals of existing cumulative temporary differences. Any federal tax benefit generated from losses in 2025 is expected to require an offsetting adjustment to the valuation allowance for deferred tax assets, and thus have no net effect on the income tax provision.

------

<u>[**Table of Contents**](#i3110ff974c884b0fab8eec36c8e490a0_7)</u>

**NeueHealth, Inc.**

**Notes to Condensed Consolidated Financial Statements**

**(Unaudited)**

**NOTE 11. REDEEMABLE NONCONTROLLING INTEREST**

Redeemable noncontrolling interests in our subsidiaries whose redemption is outside of our control are classified as temporary equity. The following table provides details of our redeemable noncontrolling interest activity for the three and six months ended June 30, 2025 and 2024 *(in thousands)*:

---

| | | |
|:---|:---|:---|
| | **2025** | **2024** |
| Balance at January 1 | $48580 | $88908 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Earnings attributable to noncontrolling interest | 770 | 4227 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Distribution to noncontrolling interest holders | (1702) | (1884) |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Measurement adjustment | 121 | 7510 |
| Balance at March 31 | $47769 | $98761 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Earnings attributable to noncontrolling interest | 1671 | (531) |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Distribution to noncontrolling interest holders | (547) | 4174 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Measurement adjustment | 6836 | 1463 |
| Balance at June 30 | $55729 | $103867 |

---

**NOTE 12. ACO REACH**

We participate in the CMS ACO REACH Model with three REACH ACOs participating through the global risk arrangement and assuming full risk for the total cost of care of aligned beneficiaries. As part of our participation in the ACO REACH Model, we are guaranteeing the performance of our care network of participating and preferred providers. The intention of the ACO REACH Model is to enhance the quality of care for Medicare FFS beneficiaries while reducing the administrative burden, supporting a focus on complex, chronically ill patients, and encouraging physician organizations that have not typically participated in Medicare FFS programs to serve Medicare FFS beneficiaries. CMS currently has the ACO REACH Model set to end with performance year 2026, on December 31, 2026.

Key components of the financial agreement for the ACO REACH Model include:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• **Performance Year Benchmark:** The target amount for Medicare expenditures on covered services (Medicare Part A and B) furnished to a REACH ACO's aligned beneficiaries during a performance year. The Performance Year Benchmark will be compared to the REACH ACO's performance year expenditures. This comparison will be used to calculate shared savings and shared losses. The Performance Year Benchmark is established at the beginning of the performance year utilizing prospective trend estimates and is subject to retrospective trend adjustments, if warranted, before the Financial Reconciliation.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• **Risk-Sharing Arrangements:** Used in determining the percent of savings and losses that REACH ACOs are eligible to receive as shared savings or may be required to repay as shared losses.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• **Financial Reconciliation:** The process by which CMS determines shared savings or shared losses by comparing the calculated total benchmark expenditures for a given REACH ACO's aligned population to the actual expenditures of that REACH ACO's aligned beneficiaries over the course of a performance year that includes various risk-mitigation options such as stop-loss reinsurance and risk corridors.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• **Risk-Mitigation Options:** For the 2024 and 2025 Performance Year, all of our REACH ACOs elected to participate in a "stop-loss arrangement" offered by CMS. The "stop-loss arrangement" is designed to reduce the financial uncertainty associated with high-cost expenditures of individual beneficiaries. Additionally, CMS has created a mandatory risk corridor program that allocates the REACH ACO's shared savings and losses in bands of percentage thresholds, after a deviation of greater than 25.0% of the Performance Year Benchmark.

**Performance Guarantees**

Through our participation in the ACO REACH Model, we determined that our arrangements with the providers of our REACH ACO beneficiaries require us to guarantee their performance to CMS. At the beginning of the performance year, we recognized the ACO REACH estimated performance year obligation and receivable for the duration of the performance year. This

------

<u>[**Table of Contents**](#i3110ff974c884b0fab8eec36c8e490a0_7)</u>

**NeueHealth, Inc.**

**Notes to Condensed Consolidated Financial Statements**

**(Unaudited)**

receivable and obligation are measured at an amount equivalent to the estimated Performance Year Benchmark per CMS that is representative of the expected Medicare expenditures for beneficiaries aligned to our REACH ACOs. As we fulfill our obligation, we amortize the guarantee on a straight-line basis for the amount that represents the completed portion of the performance obligation. The receivable is reduced as we receive payments from CMS for in-network claims or receive CMS reporting detailing out-of-network claims paid by CMS on behalf of our aligned beneficiaries. At the end of each reporting period, we estimate both in-network claims and out-of-network claims incurred by beneficiaries aligned to our REACH ACOs but not yet reported and record a reserve for the estimated amount which is included in medical costs payable on the Condensed Consolidated Balance Sheets. For each performance year, the final consideration due to the REACH ACOs by CMS (shared savings) or the consideration due to CMS by the REACH ACOs (shared loss) is reconciled in the year following the performance year. On a periodic basis CMS adjusts the estimated Performance Year Benchmark based upon revised trend assumptions and changes in attributed membership. CMS will also estimate the shared savings or loss for the REACH ACO on a quarterly basis based upon the estimated Performance Year Benchmark, changes to membership, payments made to the REACH ACO for in-network claims, out-of-network claims paid on behalf of the REACH ACO and various other assumptions including incurred but not reported reserves. The estimated Performance Year Benchmark is our best estimate of our obligation as we are unable to estimate the potential shared savings or loss due to the "stop-loss arrangement", risk corridor components of the agreement, and a number of variables including but not limited to risk ratings and benchmark trends that could have an inestimable impact on estimated future payments.

The tables below include the financial statement impacts of the performance guarantee at June 30, 2025 and December 31, 2024 and for the three and six-month periods ended June 30, 2025 and 2024 (*in thousands*):

---

| | | |
|:---|:---|:---|
| | **June 30, 2025** | **December 31, 2024** |
| ACO REACH performance year receivable<sup>(1)</sup> | $321596 | $95075 |
| ACO REACH performance year obligation | 248465 |  |

---

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<sup>(1) &nbsp;&nbsp;&nbsp;&nbsp;</sup>As of June 30, 2025, we estimate there to be in-network and out-of-network claims incurred by beneficiaries aligned to our REACH ACOs but not reported of $60.5 million related to performance year 2025 and $4.5 million related to performance year 2024; this is included in medical costs payable on the Condensed Consolidated Balance Sheets.

---

| | | | | |
|:---|:---|:---|:---|:---|
| | **Three Months Ended<br>June 30,** | **Three Months Ended<br>June 30,** | **Six Months Ended<br>June 30,** | **Six Months Ended<br>June 30,** |
| | **2025** | **2024** | **2025** | **2024** |
| Amortization of ACO REACH performance year receivable<sup>(1)</sup> | $140142 | $166099 | $276841 | $341559 |
| Amortization of ACO REACH performance year obligation | (120972) | (149047) | (248465) | (325599) |
| ACO REACH revenue | 115339 | 149802 | 239379 | 321613 |

---

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<sup>(1) &nbsp;&nbsp;&nbsp;&nbsp;</sup>The amortization of the ACO REACH performance year receivable includes $95.1 million and $115.9 million related to the amortization of the prior year receivable for the six months ended June 30, 2025 and 2024, respectively.

**NOTE 13. DECONSOLIDATION OF BRIGHT HEALTHCARE INSURANCE COMPANY OF TEXAS**

On November 29, 2023, BHIC-Texas (the "Deconsolidated Entity") was placed into liquidation and the Texas Department of Insurance was appointed as receiver. The Deconsolidated Entity's financial results are included in the Company's consolidated results through November 28, 2023, the day prior to the date of the receivership. However, under ASC 810, consolidation of a majority-owned subsidiary is precluded where control of the subsidiary does not rest with the majority owners. Once the Texas Department of Insurance was appointed as receiver of BHIC-Texas we concluded the Company no longer controlled the subsidiary, and we deconsolidated BHIC-Texas as of that date.

The deconsolidation of BHIC-Texas resulted in certain related party balances that had previously been eliminated upon consolidation to become liabilities of the Company. In 2022, BHIC-Texas entered into a risk share contract with a different

------

<u>[**Table of Contents**](#i3110ff974c884b0fab8eec36c8e490a0_7)</u>

**NeueHealth, Inc.**

**Notes to Condensed Consolidated Financial Statements**

**(Unaudited)**

NeueHealth affiliate, whereby losses incurred at BHIC-Texas over a specified medical loss ratio target were transferred from BHIC-Texas to the affiliated entity. On November 29, 2023 the accrued loss of BHIC-Texas related to the risk share contract was $124.0 million. Upon deconsolidation of BHIC-Texas, this liability is required to be recorded as risk share payable to deconsolidated entity on the Consolidated Balance Sheet. The corresponding receivable on BHIC-Texas was included in our carrying value evaluation described below.

The table below presents the balance sheet of BHIC-Texas on November 29, 2023, the date the Deconsolidated Entity was placed into receivership.

---

| | |
|:---|:---|
| Cash and cash equivalents | $60560 |
| Prepaids and other current assets | 1522 |
| Risk share receivable | 123981 |
| &nbsp;&nbsp;**Total Assets** | $186063 |
| Accounts payable | $135 |
| Medical costs payable | 3283 |
| Other current liabilities | 1523 |
| Risk adjustment payable | 89638 |
| &nbsp;&nbsp;**Total Liabilities** | 94579 |
| APIC | 204753 |
| Accumulated Deficit | (113269) |
| &nbsp;&nbsp;**Total Equity** | 91484 |
| &nbsp;&nbsp;**Total Liabilities and Equity** | $186063 |

---

Under ASC 810, *Consolidatio*n, this loss of control would likely trigger a gain or loss for the parent as the parent would remeasure its retained noncontrolling investment at fair value. Upon deconsolidation, the Company valued its investment in BHIC-Texas to be $91.5 million, which is equivalent to the Deconsolidated Entity's carrying value. Upon valuing the investment in BHIC-Texas we assessed the current expected credit loss associated with the underlying receivables; as a result of our analysis we recorded a full valuation allowance on the investment due to uncertainties related to the collection of the risk share receivable.

**NOTE 14. DISCONTINUED OPERATIONS**

In April 2023, we announced that we were exploring strategic alternatives for our California Medicare Advantage business, the Bright HealthCare reporting segment, with the focus on a potential sale. At that time, we met the criteria for "held for sale," in accordance with ASC 205-20. This represents a strategic shift that will have a material impact on our business and financial results. As such, we have reflected amounts relating to Bright HealthCare as a disposal group as part of discontinued operations. On June 30, 2023, the Company entered into a definitive agreement with Molina to sell its California Medicare Advantage business to Molina, which consisted of BND and CHP (the "Molina Purchase Agreement"). Effective as of January 1, 2024, this transaction was consummated for an aggregate purchase price of $500.0 million subject to certain contingencies adjustments relating to Tangible Net Equity ("TNE"). Upon completion of the sale, the Bright HealthCare reporting unit of our discontinued operations was no longer included in our operations. The Consolidation and Adjustment Escrow review has been completed and $61.1 million was released from escrow to the Company on March 17, 2025.

In October 2022, we announced that we will no longer offer commercial plans through our Bright HealthCare - Commercial segment in 2023. As a result, we exited the Commercial marketplace effective December 31, 2022. We determined this exit represented a strategic shift that will have a material impact on our business and financial results that requires presentation as discontinued operations.

While we are no longer offering plans in the Commercial marketplace as of December 31, 2022, we will continue to be involved in the states where we formerly operated in, as we support run out activities of medical claims incurred in the 2022 plan year and perform other activities necessary to wind down our operations in each state. We were substantially complete

------

<u>[**Table of Contents**](#i3110ff974c884b0fab8eec36c8e490a0_7)</u>

**NeueHealth, Inc.**

**Notes to Condensed Consolidated Financial Statements**

**(Unaudited)**

with medical claim payments as of the end of 2023, and we will continue to make remaining medical claim payments and payments towards the remaining risk adjustment obligations through 2025 and into 2026.

The financial results of discontinued operations by major line item were as follows *(in thousands)*:

---

| | | | | |
|:---|:---|:---|:---|:---|
| | **Three Months Ended<br>June 30,** | **Three Months Ended<br>June 30,** | **Six Months Ended<br>June 30,** | **Six Months Ended<br>June 30,** |
| | **2025** | **2024** | **2025** | **2024** |
| Revenue: |  |  |  |  |
| &nbsp;&nbsp;&nbsp;Premium revenue | $(221) | $(11124) | $(543) | $(11339) |
| &nbsp;&nbsp;&nbsp;Investment income | 815 | 1226 | 1757 | 2794 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**Total revenue from discontinued operations** | 594 | (9898) | 1214 | (8545) |
| Operating expenses: |  |  |  |  |
| &nbsp;&nbsp;&nbsp;Medical costs | 1162 | 50 | (41) | (3709) |
| &nbsp;&nbsp;&nbsp;Operating costs | (646) | 2275 | 1358 | 8481 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**Total operating expenses from discontinued operations** | 516 | 2325 | 1317 | 4772 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Operating loss from discontinued operations | 78 | (12223) | (103) | (13317) |
| &nbsp;&nbsp;&nbsp;Interest expense | 7815 | 7308 | 17066 | 16073 |
| &nbsp;&nbsp;&nbsp;Gain on sale of DocSquad business |  | (991) |  | (991) |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**Loss from discontinued operations before income taxes** | (7737) | (18540) | (17169) | (28399) |
| Income tax expense (benefit) | 649 | (101) | 627 | (95) |
| &nbsp;&nbsp;&nbsp;**Net loss from discontinued operations** | $(8386) | $(18439) | $(17796) | $(28304) |

---

The following table presents cash flows from operating and investing activities for discontinued operations for the six months ended June 30, 2025 and 2024 *(in thousands)*:

---

| | | |
|:---|:---|:---|
| | **Six Months Ended June 30,** | **Six Months Ended June 30,** |
| | **2025** | **2024** |
| Cash used in operating activities - discontinued operations | $(17999) | $(59514) |
| Cash provided by investing activities - discontinued operations | 61208 | 199702 |
| **Supplemental disclosure of cash flow information:** |  |  |
| &nbsp;&nbsp;&nbsp;Cash paid for interest | $60 | $4242 |

---

------

<u>[**Table of Contents**](#i3110ff974c884b0fab8eec36c8e490a0_7)</u>

**NeueHealth, Inc.**

**Notes to Condensed Consolidated Financial Statements**

**(Unaudited)**

Assets and liabilities of discontinued operations were as follows *(in thousands)*:

---

| | | |
|:---|:---|:---|
| | **June 30, 2025** | **December 31, 2024** |
| | **Total** | **Total** |
| **Assets** | | |
| Current assets: |  |  |
| &nbsp;&nbsp;Cash and cash equivalents | $81313 | $102110 |
| &nbsp;&nbsp;Short-term investments | 7506 | 7533 |
| &nbsp;&nbsp;Consideration due from Molina |  | 61139 |
| &nbsp;&nbsp;Prepaids and other current assets | 985 | 2224 |
| &nbsp;&nbsp;&nbsp;&nbsp;**Current assets of discontinued operations** | 89804 | 173006 |
| &nbsp;&nbsp;&nbsp;&nbsp;**Total assets of discontinued operations** | $89804 | $173006 |
| **Liabilities** |  |  |
| Current liabilities: |  |  |
| &nbsp;&nbsp;Medical costs payable | $2133 | $7031 |
| &nbsp;&nbsp;Accounts payable | 3931 | 9052 |
| &nbsp;&nbsp;Risk adjustment payable | 271839 | 276835 |
| &nbsp;&nbsp;Other current liabilities | 55896 | 51733 |
| &nbsp;&nbsp;&nbsp;&nbsp;**Current liabilities of discontinued operations** | 333799 | 344651 |
| &nbsp;&nbsp;&nbsp;&nbsp;**Total liabilities of discontinued operations** | $333799 | $344651 |

---

**California Medicare Advantage Sale:** On June 30, 2023, the Company entered into a definitive agreement with Molina to sell its California Medicare Advantage business, which consisted of BND and CHP, for total purchase consideration of $600.0 million, subject to regulatory approval and other closing conditions. Subsequently, on December 13, 2023 we announced that we entered an amendment (the "Amendment") with Molina which reduced the purchase price of our California Medicare Advantage business from $600.0 million to $500.0 million. Upon closing on the sale, effective January 1, 2024, the $500.0 million purchase price included $167.3 million of purchase price adjustments subject to contingencies and adjustments relating to TNE.

The Consolidation and Adjustment Escrow review has been completed and $61.1 million was released from escrow to the Company on March 17, 2025. The remaining purchase price consideration subject to contingencies and adjustments as of June 30, 2025 is as follows *(in thousands)*:

---

| | |
|:---|:---|
| Indemnity Escrow Amount <sup>(1)</sup> | 10000 |
| Total consideration subject to contingencies at closing | $10000 |

---

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<sup>(1)</sup> For 18 months post-closing date, the Company will indemnify Molina against and are liable to Molina for any and all losses incurred by Molina resulting from breach or inaccuracy of warranties and representations made, breach or failure to perform any covenant of the Molina Purchase Agreement, among others. As the Indemnity Escrow Amount is subject to these conditions for 18 months post close, the Company will recognize this amount in the fair value of consideration received no earlier than the point at which 18 months have passed, on July 2, 2025. The amount recognized will be equal to the $10.0 million Indemnity Escrow Amount less any agreed upon or actual adjudicated losses. In July 2025, the

------

<u>[**Table of Contents**](#i3110ff974c884b0fab8eec36c8e490a0_7)</u>

**NeueHealth, Inc.**

**Notes to Condensed Consolidated Financial Statements**

**(Unaudited)**

Company received $2.0 million of the Indemnity Escrow Amount. The remaining $8.0 million of related claims against the Indemnity Escrow Amount are still under review.

As the conditions surrounding collection of the Indemnity Escrow Amount were subject to contingencies that are largely outside of the Company's control, we did not record any contingent consideration receivable related to the amount as of June 30, 2025.

At the time of the sale, our investment in the California MA business was calculated as follows *(in thousands)*:

---

| | |
|:---|:---|
| Total assets <sup>(1)</sup> | $647254 |
| Total liabilities | (323038) |
| Investment in California MA Business | $324216 |

---

Refer to Note 19 of the 2024 Form 10-K for discussion of the gain on sale recorded in the fourth quarter of 2024. As of June 30, 2024, the company recorded no gain or loss associated with the sale of the California Medicare Advantage business *(in thousands)*:

---

| | |
|:---|:---|
| Sale price of California MA Business | $500000 |
| &nbsp;&nbsp;Less: Portion of sale price subject to contingencies | (167326) |
| &nbsp;&nbsp;Less: Investment in California MA Business | (324216) |
| &nbsp;&nbsp;Less: Transactions costs contingent on closing of sale | (8458) |
| Gain or loss on sale of California MA Business | $— |

---

Upon the close of the sale, we ceased having a controlling financial interest over BND and CHP and have not retained any investments in the former subsidiaries. Molina is not a related party and subsequent to the close of the sale BND and CHP are no longer considered related parties to the Company.

**Revenue Recognition:** We record adjustments for changes to the risk adjustment balances for individual policies in premium revenue. The risk adjustment program adjusts premiums based on the demographic factors and health status of each consumer as derived from current-year medical diagnoses as reported throughout the year. Under the risk adjustment program, a risk score is assigned to each covered consumer to determine an average risk score at the individual and small-group level by legal entity in a particular market in a state. Additionally, an average risk score is determined for the entire subject population for each market in each state. Settlements are determined on a net basis by legal entity and state and are made in the middle of the year following the end of the contract year. Each health insurance issuer's average risk score is compared to the state's average risk score. Risk adjustment is subject to audit by the U.S. Department of Health and Human Services ("HHS"), which could result in future payments applicable to benefit years.

------

<u>[**Table of Contents**](#i3110ff974c884b0fab8eec36c8e490a0_7)</u>

**NeueHealth, Inc.**

**Notes to Condensed Consolidated Financial Statements**

**(Unaudited)**

**Fixed Maturity Securities:** Held-to-maturity securities are reported at amortized cost as of June 30, 2025 and December 31, 2024. The following is a summary of our investment securities *(in thousands)*:

---

| | | | | |
|:---|:---|:---|:---|:---|
| | **June 30, 2025** | **June 30, 2025** | **June 30, 2025** | **June 30, 2025** |
| | **Amortized** <br>**Cost** | **Gross**<br>**Unrealized** <br>**Gains** | **Gross**<br>**Unrealized** <br>**Losses** | **Carrying** <br>**Value** |
| Cash equivalents | $74931 | $— | $— | $74931 |
| Held to maturity: |  |  |  |  |
| &nbsp;&nbsp;U.S. government and agency obligations | 7409 |  |  | 7409 |
| &nbsp;&nbsp;Corporate obligations |  |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Total held-to-maturity securities | 7506 |  |  | 7506 |
| &nbsp;&nbsp;&nbsp;&nbsp;Total investments | $82437 | $— | $— | $82437 |

---

---

| | | | | |
|:---|:---|:---|:---|:---|
| | **December 31, 2024** | **December 31, 2024** | **December 31, 2024** | **December 31, 2024** |
| | **Amortized** <br>**Cost** | **Gross**<br>**Unrealized** <br>**Gains** | **Gross**<br>**Unrealized** <br>**Losses** | **Carrying** <br>**Value** |
| Cash equivalents | $82043 | $6 | $— | $82049 |
| Held to maturity: |  |  |  |  |
| &nbsp;&nbsp;U.S. government and agency obligations | 7430 |  |  | 7430 |
| &nbsp;&nbsp;Corporate obligations | 103 |  |  | 103 |
| &nbsp;&nbsp;&nbsp;&nbsp;Total held-to-maturity securities | 7533 |  |  | 7533 |
| &nbsp;&nbsp;&nbsp;&nbsp;Total investments | $89576 | $6 | $— | $89582 |

---

We believe that we will collect the principal and interest due on our debt securities that have an amortized cost in excess of fair value. The unrealized losses were primarily caused by interest rate increases. At each reporting period, we evaluate securities for impairment when the fair value of the investment is less than its amortized cost. We evaluated the underlying credit quality and credit ratings of the issuers, noting no significant deterioration since purchase.

**Fair Value Measurements:** Certain assets and liabilities are measured at fair value in the condensed consolidated financial statements or have fair values disclosed in the notes to the condensed consolidated financial statements. These assets and liabilities are classified into one of three levels of a hierarchy defined by GAAP.

**Level 1:** Unadjusted quoted prices in active markets that are accessible at the measurement date for identical, unrestricted assets or liabilities.

**Level 2:** Quoted prices for similar assets or liabilities in active markets or quoted prices in markets that are not active, or inputs that are observable, either directly or indirectly, for substantially the full term of the asset or liability.

**Level 3:** Prices or valuation techniques that require inputs that are both significant to the fair value measurement and unobservable (i.e., supported by little or no market activity).

For a description of the methods and assumptions that are used to estimate the fair value and determine the fair value hierarchy classification of each class of financial instrument see Note 19 to the audited consolidated financial statements included in our 2024 Form 10-K.

As of June 30, 2025, investments and cash equivalents within our discontinued operations were comprised of $80.8 million and $1.7 million with fair value measurements of Level 1 and Level 2, respectively. As of December 31, 2024, the investments and

------

<u>[**Table of Contents**](#i3110ff974c884b0fab8eec36c8e490a0_7)</u>

**NeueHealth, Inc.**

**Notes to Condensed Consolidated Financial Statements**

**(Unaudited)**

cash equivalents within our discontinued operations were comprised of $87.8 million and $1.8 million with fair value measurements of Level 1 and Level 2, respectively. All investments and cash equivalents within our discontinued operations is classified as restricted.

**Medical Costs Payable:** The table below details the components making up the medical costs payable within current liabilities of discontinued operations *(in thousands)*:

---

| | | |
|:---|:---|:---|
| | **Bright HealthCare - Commercial** | **Bright HealthCare - Commercial** |
| | **June 30, 2025** | **December 31, 2024** |
| Claims unpaid | $1930 | $5760 |
| Incurred but not reported (IBNR) | 203 | 1271 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Total medical costs payable of discontinued operations | $**2133** | $**7031** |

---

**Risk Adjustment:** On March 13, 2025, our insurance subsidiaries in Colorado and Florida entered into modified repayment agreements with respect to the remaining unpaid amount of their risk adjustment obligations for an aggregate amount of $271.8 million. The remaining amount owed under the Modified Repayment Agreements is due September 15, 2026 and bears interest at a rate of 11.5% per annum. The remaining amount due relating to the risk adjustment repayment agreements, our risk adjustment payable liability, was $271.8 million and $276.8 million as of June 30, 2025 and December 31, 2024, respectively. During the first quarter of 2025, our insurance subsidiary in Illinois repaid the entirety of its outstanding risk adjustment obligation. In July 2025, our Florida and Colorado insurance subsidiaries paid a combined $12.5 million towards the risk adjustment interest obligation.

**Restricted Capital and Surplus:** Our regulated insurance legal entities are required by statute to meet and maintain a minimum level of capital as stated in applicable state regulations, such as risk-based capital requirements. These balances are monitored regularly to ensure compliance with these regulations. For the period ended June 30, 2025, we are out of compliance with the minimum levels for certain of our regulated insurance legal entities.

**NOTE 15. SUBSEQUENT EVENTS**

We have evaluated the events and transactions that have occurred through the date at which the condensed consolidated financial statements were issued. Other than those described in the footnotes above, no additional events or transactions have occurred that may require adjustment to the condensed consolidated financial statements or disclosures.

------

<u>[**Table of Contents**](#i3110ff974c884b0fab8eec36c8e490a0_7)</u>

**ITEM 2. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS**

*The following discussion and analysis is intended to help the reader understand our business, financial condition, results of operations, liquidity and capital resources. This discussion should be read in conjunction with our unaudited condensed consolidated financial statements and accompanying notes and the "Risk Factors" included elsewhere in this Quarterly Report on Form 10-Q and our audited consolidated financial statements and the accompanying notes as well as the "Risk Factors" and "Management's Discussion and Analysis of Financial Condition and Results of Operations" included in our 2024 Form 10-K. Unless the context otherwise indicates or requires, the terms "we", "our", and the "Company" as used herein refer to NeueHealth, Inc. and its consolidated subsidiaries.*

**Business Overview**

NeueHealth, Inc. was founded in 2015 to transform healthcare. Although the business has evolved, our commitment to making high-quality, coordinated healthcare accessible and affordable to all populations remains unchanged. NeueHealth consists of two reportable segments within our continuing operations: NeueCare and NeueSolutions. Additionally, we have one reportable segment in our discontinued operations: Bright HealthCare - Commercial.

***NeueCare.*** Our value-driven care delivery business that manages risk in partnership with external payors and serves all populations across the ACA Marketplace, Medicare, and Medicaid. NeueCare aims to significantly reduce the friction and current lack of coordination between payors and providers to enable a truly consumer-centric healthcare experience. As of June 30, 2025, NeueCare delivers high-quality in-person and virtual clinical care through its 67 owned primary care clinics within an integrated care delivery system. Through these risk-bearing clinics and our affiliated network of care providers, NeueCare maintained approximately 547,000 consumers, inclusive of 504,000 value-based consumers and 43,000 fee-for-service consumers.

***NeueSolutions.*** Our provider enablement business that includes a suite of technology, services, and clinical care solutions that empower providers to thrive in performance-based arrangements. As of June 30, 2025, NeueSolutions had approximately 34,000 value-based care consumers attributed to its REACH ACOs, 8,000 value-based care consumers attributed to participation in the Medicare Shared Savings Program ("MSSP"), and 148,000 enablement services lives.

***Bright HealthCare - Commercial.*** Included in our discontinued operations, our Commercial healthcare financing and distribution business focused on commercial plans. In October 2022, we announced that we would no longer offer commercial health plans effective at the end of 2022.

**Business Update** 

NeueHealth delivered another strong quarter of financial results, continuing to build on the momentum we established across our NeueCare and NeueSolutions segments this year. Generating Adjusted EBITDA profitability for the sixth consecutive quarter, we continue to demonstrate the success of our focused business, strong fundamental execution, and disciplined approach to driving long-term, profitable growth.

This quarter, we have seen strong results in all key product categories we serve – ACA Marketplace, Medicare, and Medicaid – leading to 45% aggregate growth in consumers served over second quarter last year. We continue to drive differentiated results across products by deepening our commitment to placing the consumer at the center of everything we do, increasing access to high-quality care for all populations, and enhancing and evolving our data and analytics capabilities into an end-to-end, value-based care enablement platform. We believe this platform is a core component of our model, powering our business into the future and fueling our future performance, growth, and success.

Through the first half of this year, we have set a solid foundation to continue to evolve and advance our care model, build on the payor and provider partnerships we've established, and bring high-quality, coordinated care to more consumers. Our continued strong financial performance gives us confidence that we are well positioned in the market, and most importantly, delivering value to consumers, providers, and payors across the industry by creating a seamless, more coordinated care experience for all.

------

<u>[**Table of Contents**](#i3110ff974c884b0fab8eec36c8e490a0_7)</u>

***NEA Merger Agreement***

On December 23, 2024, NeueHealth entered into the NEA Merger Agreement with NH Holdings 2025, Inc., a Delaware corporation ("Parent"), and NH Holdings Acquisition 2025, Inc., a Delaware corporation and a wholly owned subsidiary of Parent ("Merger Sub"), pursuant to which and subject to the conditions set forth therein, Merger Sub will merge with and into the Company (the "NEA Merger"), with the Company surviving the NEA Merger as a wholly owned subsidiary of Parent. Parent and Merger Sub are indirectly controlled by private investment funds affiliated with New Enterprise Associates, Inc ("NEA"). If the NEA Merger is consummated, the Company's common stock will be delisted from the New York Stock Exchange and deregistered under the Securities Exchange Act of 1934, as amended.

**Key Metrics and Non-GAAP Financial Measures**

In addition to our GAAP financial information, we use several operating and financial metrics to evaluate our business, measure our performance, identify trends affecting our business, formulate our business plan and make strategic decisions. The following table includes two key metrics used to measure our performance: approximate consumers and patients served as of June 30, 2025 and 2024.

---

| | | |
|:---|:---|:---|
| | **As of June 30,** | **As of June 30,** |
| | **2025** | **2024** |
| Value-Based Consumers served | 546,000 | 364,000 |
| Enablement Services Lives | 148,000 | 113,000 |

---

***Value-Based Care Consumers***

Value-based care consumers are consumers attributed to providers contracted under various value-based care delivery models in which the responsibility for control of an attributed patient's medical care is transferred, in part or wholly, to our NeueHealth owned or affiliated medical groups. We believe growth in the number of value-based care consumers is a key indicator of the performance of our NeueHealth business. It also informs our management of the operational, clinical, technological and administrative functional area needs that will require further investment to support expected future patient growth and effective medical management practices. We saw a year over year increase in value-based care consumers of approximately 182,000 consumers; driven by an increase of 184,000 value-based care consumers through our third-party payor relationships and 8,000 new value-based care consumers aligned to our participation in MSSP beginning January 1, 2025, partially offset by a decline of approximately 10,000 ACO REACH lives. Our focus is to continue to grow the number of value-based care consumers through third-party payor relationships.

***Enablement Services Lives***

Enablement services lives are members attributed to NeueHealth by provider partner groups that are outside of the NeueHealth owned network. We bring the people, process, and technology platforms necessary to manage the administrative support for these value-based and risk arrangement members, on behalf of our provider partners. As a result of the value we drive, we ended the quarter with approximately 148,000 enablement services lives under contract within those organizations.

---

| | | | | |
|:---|:---|:---|:---|:---|
| | **Three Months Ended June 30,** | **Three Months Ended June 30,** | **Six Months Ended June 30,** | **Six Months Ended June 30,** |
| *($ in thousands)* | **2025** | **2024** | **2025** | **2024** |
| **Income (Loss) from continuing operations before income taxes** | $6817 | $(39446) | $5490 | $(33095) |
| **Adjusted EBITDA**<sup>(1)</sup> | $19020 | $3962 | $32499 | $7618 |

---

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<sup>(1)</sup>See "Non-GAAP Financial Measures" below for reconciliations to the most directly comparable financial measures calculated in accordance with GAAP and related disclosures.

------

<u>[**Table of Contents**](#i3110ff974c884b0fab8eec36c8e490a0_7)</u>

**Non-GAAP Financial Measures**

***Adjusted EBITDA***

We define Adjusted EBITDA as Net Loss excluding loss from discontinued operations, interest expense, income taxes, depreciation and amortization, transaction costs, share-based and other long-term compensation expense, impact of troubled debt restructuring, restructuring and contract termination costs, impairment of goodwill and long-lived assets, losses related to the bankruptcy of one of our ACO REACH partners, impact of classifying certain of our operations as held-for-sale, and changes in the fair value of derivatives. Adjusted EBITDA has been presented in this Quarterly Report on Form 10-Q as a supplemental measure of financial performance that is not required by, or presented in accordance with, GAAP, because we believe it assists management and investors in comparing our operating performance across reporting periods on a consistent basis by excluding items that we do not believe are indicative of our core operating performance. Management believes Adjusted EBITDA is useful to investors in highlighting trends in our operating performance, while other measures can differ significantly depending on long-term strategic decisions regarding capital structure, the tax jurisdictions in which we operate and capital investments. Management uses Adjusted EBITDA to supplement GAAP measures of performance in the evaluation of the effectiveness of our business strategies, to make budgeting decisions, to establish discretionary annual incentive compensation and to compare our performance against that of other peer companies using similar measures. Management supplements GAAP results with non-GAAP financial measures to provide a more complete understanding of the factors and trends affecting the business than GAAP results alone.

Adjusted EBITDA is not a recognized term under GAAP and should not be considered as an alternative to net income (loss) as a measure of financial performance or cash provided by operating activities as a measure of liquidity, or any other performance measure derived in accordance with GAAP. Additionally, this measure is not intended to be a measure of free cash flow available for management's discretionary use as we do not consider certain cash requirements such as interest payments, tax payments and debt service requirements. The presentation of this measure has limitations as an analytical tool and should not be considered in isolation, or as a substitute for analysis of our results as reported under GAAP. Because not all companies use identical calculations, the presentation of this measure may not be comparable to other similarly titled measures of other companies and can differ significantly from company to company.

------

<u>[**Table of Contents**](#i3110ff974c884b0fab8eec36c8e490a0_7)</u>

The following table provides a reconciliation of net loss to Adjusted EBITDA for the periods presented:

---

| | | | | |
|:---|:---|:---|:---|:---|
| | **Three Months Ended June 30,** | **Three Months Ended June 30,** | **Six Months Ended June 30,** | **Six Months Ended June 30,** |
|<br>*($ in thousands)* | **2025** | **2024** | **2025** | **2024** |
| **Net loss** | $(1548) | $(57698) | $(12396) | $(61875) |
| &nbsp;&nbsp;&nbsp;Loss from Discontinued Operations | 8386 | 18439 | 17796 | 28304 |
| **EBITDA adjustments from continuing operations** |  |  |  |  |
| &nbsp;&nbsp;&nbsp;Interest expense | 6878 | 4110 | 13515 | 7040 |
| &nbsp;&nbsp;&nbsp;Income tax expense | (21) | (187) | 90 | 476 |
| &nbsp;&nbsp;&nbsp;Depreciation and amortization <sup>(g)</sup> | 3555 | 3484 | 7114 | 7551 |
| &nbsp;&nbsp;&nbsp;Transaction costs <sup>(a)</sup> | (1011) | 844 | 602 | 1965 |
| &nbsp;&nbsp;&nbsp;Share-based and other long-term incentive compensation expense <sup>(b)</sup> | 2012 | 21236 | 7658 | 39862 |
| &nbsp;&nbsp;&nbsp;Gain on troubled debt restructuring |  |  |  | (30311) |
| &nbsp;&nbsp;&nbsp;Change in fair value of warrant liability <sup>(c)</sup> | 562 | (2213) | (2087) | (4285) |
| &nbsp;&nbsp;&nbsp;Restructuring and contract termination costs <sup>(d)</sup> | 207 | 239 | 207 | 181 |
| &nbsp;&nbsp;&nbsp;Held-for-sale operations <sup>(e)</sup> |  | 16671 |  | 18294 |
| &nbsp;&nbsp;&nbsp;ACO REACH care partner bankruptcy <sup>(f)</sup> |  | (963) |  | 285 |
| &nbsp;&nbsp;&nbsp;Impairment of goodwill and long-lived assets |  |  |  | 131 |
| **EBITDA adjustments from continuing operations** | $12182 | $43221 | $27099 | $41189 |
| **Adjusted EBITDA** | $19020 | $3962 | $32499 | $7618 |

---

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a)Transaction costs include accounting, tax, valuation, consulting, legal and investment banking fees directly relating to financing initiatives and acquisitions or dispositions. These costs can vary from period to period and impact comparability, and we do not believe such transaction costs reflect the ongoing performance of our business.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b)Represents non-cash compensation expense related to stock option and restricted stock unit award grants, which can vary from period to period based on several factors, including the timing, quantity and grant date fair value of the awards. Also includes $0.1 million and $0.2 million of compensation expense that was recognized for the cancellation of P-Unit Awards in relation to our purchase of the minority interest in Centrum for the three and six months ended June 30, 2025. There was no equivalent compensation expense included for the three and six months ended June 30, 2024.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(c)Represents the non-cash change in the fair value of the warrant liability established for warrants included in our financing arrangements, which are remeasured at fair value each reporting period.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(d)Restructuring and contract termination costs represent severance costs as part of a workforce reduction, amounts paid for early termination of leases, and impairment of certain long-lived assets primarily relating to our decision to exit the Commercial business for the 2023 plan year.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(e)Beginning in the second quarter of 2024, Adjusted EBITDA excludes the impact of our operations classified as held-for-sale that were subsequently sold in November 2024.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(f)Represents the costs incurred as a result of one of our ACO REACH care partners filing for bankruptcy; includes the full allowance established for the outstanding receivable and ongoing costs incurred to manage and provide service to members attributed to the care partner that would have otherwise been reimbursed prior to the care partner's bankruptcy.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(g)Adjustment has been updated to remove the impact of our held-for-sale operations that are adjusted for in their entirety as described in (e).

------

<u>[**Table of Contents**](#i3110ff974c884b0fab8eec36c8e490a0_7)</u>

**Results of Operations**

The following table summarizes our unaudited Condensed Consolidated Statements of Income (Loss) data and other financial information for the three and six months ended June 30, 2025 and 2024.

---

| | | | | |
|:---|:---|:---|:---|:---|
| *($ in thousands)* | **Three Months Ended<br>June 30,** | **Three Months Ended<br>June 30,** | **Six Months Ended<br>June 30,** | **Six Months Ended<br>June 30,** |
| **Condensed Consolidated Statements of Income (loss) and operating data:** | **2025** | **2024** | **2025** | **2024** |
| Revenue: |  |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Capitated revenue | $82532 | $64005 | $163519 | $125471 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;ACO REACH revenue | 115339 | 149802 | 239379 | 321613 |
| &nbsp;&nbsp;&nbsp;&nbsp;Service revenue | 10420 | 12076 | 20254 | 23691 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Investment income | 791 | 108 | 1717 | 311 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**Total revenue** | 209082 | 225991 | 424869 | 471086 |
| Operating expenses: |  |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Medical costs | 146410 | 177681 | 307304 | 374555 |
| &nbsp;&nbsp;&nbsp;&nbsp;Operating costs | 44860 | 70470 | 93533 | 137231 |
| &nbsp;&nbsp;&nbsp;&nbsp;Intangible assets impairment |  | 11411 |  | 11411 |
| &nbsp;&nbsp;&nbsp;&nbsp;Depreciation and amortization | 3555 | 3978 | 7114 | 8540 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**Total operating expenses** | 194825 | 263540 | 407951 | 531737 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**Operating income (loss)** | 14257 | (37549) | 16918 | (60651) |
| &nbsp;&nbsp;&nbsp;&nbsp;Interest expense | 6878 | 4110 | 13515 | 7040 |
| &nbsp;&nbsp;&nbsp;&nbsp;Warrant expense (income) | 562 | (2213) | (2087) | (4285) |
| &nbsp;&nbsp;&nbsp;&nbsp;Gain on troubled debt restructuring |  |  |  | (30311) |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**Income (Loss) from continuing operations before income taxes** | 6817 | (39446) | 5490 | (33095) |
| &nbsp;&nbsp;&nbsp;&nbsp;Income tax (benefit) expense | (21) | (187) | 90 | 476 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**Net income (loss) from continuing operations** | 6838 | (39259) | 5400 | (33571) |
| &nbsp;&nbsp;&nbsp;&nbsp;Loss from discontinued operations, net of tax | (8386) | (18439) | (17796) | (28304) |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**Net Loss** | (1548) | (57698) | (12396) | (61875) |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Net income from continuing operations attributable to noncontrolling interests | (8507) | (932) | (9398) | (12669) |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Series A preferred stock dividend accrued | (10981) | (10422) | (21710) | (20716) |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Series B preferred stock dividend accrued | (2465) | (2338) | (4872) | (4648) |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**Net loss attributable to NeueHealth, Inc. common shareholders** | $(23501) | $(71390) | $(48376) | $(99908) |
| Adjusted EBITDA | $19020 | $3962 | $32499 | $7618 |
| Operating Cost Ratio <sup>(1)</sup> | 21.5% | 31.1% | 22.0% | 29.1% |

---

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(1)Operating Cost Ratio is defined as operating costs divided by total revenue.

Total revenues decreased by $16.9 million, or 7.5%, for the three months ended June 30, 2025 and $46.2 million or 9.8% for the six months ended June 30, 2025, as compared to the same periods in 2024. These decreases were primarily driven by a decrease of approximately 10,000 beneficiaries aligned to our REACH ACOs resulting in decreased ACO REACH revenue of $34.5 million and $82.2 million for the three and six months ended June 30, 2025 as compared to the same periods in 2024.

------

<u>[**Table of Contents**](#i3110ff974c884b0fab8eec36c8e490a0_7)</u>

These decreases were offset by increases in our capitated revenue of $18.5 million and $38.0 million for the three and six months ended June 30, 2025 as compared to the same periods in 2024. The increase in capitated revenue is primarily a result of increased membership through our third-party payor contracts as compared to the three and six months ended June 30, 2024.

Medical costs decreased by $31.3 million, or 17.6%, for the three months ended June 30, 2025 as compared to the same period in 2024. Medical costs decreased by $67.3 million or 18.0%, for the six months ended June 30, 2025 as compared to the same period in 2024. The decrease in medical costs was primarily driven by a decrease in beneficiaries aligned to our REACH ACOs.

Operating costs decreased by $25.6 million, or 36.3%, for the three months ended June 30, 2025 as compared to the same period in 2024. Operating costs decreased by $43.7 million, or 31.8%, for the six months ended June 30, 2025 as compared to the same period in 2024.The decrease in operating costs was primarily driven by a decrease in compensation related costs which is a result of decreases in employee headcount.

Our operating cost ratio of 21.5% and 22.0% for the three and six months ended June 30, 2025, decreased 980 and 710 basis points compared to the same periods in 2024, respectively. The decrease is driven by operating costs decreasing at a greater rate relative to the decrease in revenue, which is due to the decrease in compensation related costs - part of our on-going restructuring efforts.

For each of the three and six months ended June 30, 2024 we recognized $11.4 million in impairments of intangible assets as a result of classifying AMD as held-for-sale. In our held-for-sale analysis we concluded the carrying value of the AMD disposal group exceeded its estimated fair value set equivalent to an expected sale price; as such we fully impaired all long-lived assets. There was no equivalent activity for the three and six months ended June 30, 2025.

Depreciation and amortization decreased by $0.4 million and $1.4 million for the three and six months ended June 30, 2025 as compared to the same periods in 2024. The decrease is primarily driven by a corresponding decrease in property and equipment assets as well as intangible assets.

Interest expense increased $2.8 million and $6.5 million for the three and six months ended June 30, 2025 as compared to the same periods in 2024. The increase is primarily due to the compounding effect of the paid-in-kind interest applied to the principal balance.

We recognized warrant expense of $0.6 million and warrant income of $2.1 million for the three and six months ended June 30, 2025, respectively, as compared to warrant income of $2.2 million and $4.3 million in the same period in 2024. The change in warrant (income) expense recognized is directly tied to fluctuations in the market price of the common stock over the period.

Income tax was a benefit of $21.0 thousand and $0.2 million for the three months ended June 30, 2025 and 2024, respectively. Income tax was an expense of $0.1 million and $0.5 million for the six months ended June 30, 2025 and 2024, respectively. The impact from income taxes varies from the federal statutory rate of 21% due to state income taxes, changes in the valuation allowance for deferred tax assets and adjustments for permanent differences. For both periods, the benefit and expense largely relates to estimated state income taxes attributable to income earned in separate filing states without state net operating loss carryforwards and in combined filing states that restrict which entities within the group may use specific net operating loss carryforwards.

Loss from discontinued operations decreased by $10.1 million and $10.5 million for the three and six months ended June 30, 2025 as compared to the same periods in 2024, respectively. The decrease is attributable to being further into the runout of our Commercial business as of June 30, 2025 compared to June 30, 2024 thus incurring less operating costs as the resources needed for the runout operations have further decreased.

------

<u>[**Table of Contents**](#i3110ff974c884b0fab8eec36c8e490a0_7)</u>

---

| | | | | |
|:---|:---|:---|:---|:---|
| ***NeueCare*** | | | | |
| *($ in thousands)* | **Three Months Ended<br>June 30,** | **Three Months Ended<br>June 30,** | **Six Months Ended<br>June 30,** | **Six Months Ended<br>June 30,** |
| **Statement of income (loss) and operating data:** | **2025** | **2024** | **2025** | **2024** |
| Revenue: |  |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Capitated revenue | $81407 | $64005 | $162394 | $125471 |
| &nbsp;&nbsp;&nbsp;&nbsp;Service revenue | 6874 | 9803 | 13138 | 19333 |
| &nbsp;&nbsp;&nbsp;&nbsp;Investment income | 120 | 21 | 477 | 21 |
| &nbsp;&nbsp;&nbsp;&nbsp;Total unaffiliated revenue | $88401 | $73829 | $176009 | $144825 |
| &nbsp;&nbsp;&nbsp;&nbsp;Affiliated revenue | 3227 | 3156 | 6136 | 5783 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**Total segment revenue** | $91628 | $76985 | $182145 | $150608 |
| Operating expenses |  |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Medical costs | $36723 | $33579 | $74241 | $61015 |
| &nbsp;&nbsp;&nbsp;&nbsp;Operating costs | 28936 | 34676 | 56146 | 67265 |
| &nbsp;&nbsp;&nbsp;&nbsp;Intangible assets impairment |  | 11411 |  | 11411 |
| &nbsp;&nbsp;&nbsp;&nbsp;Depreciation and amortization | 2757 | 3221 | 5539 | 7007 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**Total operating expenses** | 68416 | 82887 | 135926 | 146698 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**Operating income (loss)** | $23212 | $(5902) | $46219 | $3910 |

---

NeueCare's capitated revenue increased by $17.4 million or 27.2% for the three months ended June 30, 2025 as compared to the same period in 2024. NeueCare's capitated revenue increased by $36.9 million or 29.4% for the six months ended June 30, 2025 as compared to the same period in 2024. The increase was a result of both rate increases in our full risk contracts with third-party payors and increased membership through our third-party payor contracts as compared to the three and six months ended June 30, 2024.

NeueCare's service revenue decreased $2.9 million for the three months ended June 30, 2025 as compared to the same period in 2024. NeueCare's service revenue decreased $6.2 million for the six months ended June 30, 2025 as compared to the same period in 2024. The decrease in NeueCare's service revenue for the three and six months ended June 30, 2025 was primarily driven by our sale of AMD in November 2024.

NeueCare's investment income increased by $0.1 million and $0.5 million for the three and six months ended June 30, 2025 as compared to the same periods in 2024. The investment income in the current year is attributable to a financial guarantee with a third-party payor invested in a certificate of deposit as well as funds invested in a money market fund; there were no equivalent investments in the same period in 2024.

Affiliated revenue increased by $0.1 million and $0.4 million for the three and six months ended June 30, 2025 as compared to the same periods in 2024, primarily attributable to fluctuations in ACO surplus at our owned providers.

NeueCare's medical costs increased by $3.1 million for the three months ended June 30, 2025 as compared to the same period in 2024. NeueCare's medical costs increased by $13.2 million for the six months ended June 30, 2025 as compared to the same period in 2024. The increase is primarily a result of rate increases in our full risk contracts with third-party payors. The increase is also a result of increases in our value-based care lives through third-party payor contracts including increases of $1.0 million and $3.6 million in provider capitation paid to our affiliate partners for the three and six months ended June 30, 2025, respectively.

Operating costs for the NeueCare segment decreased $5.7 million and $11.1 million for the three and six months ended June 30, 2025, as compared to the same periods in 2024. The decrease is primarily driven by a decrease in payroll expense due to our divestiture of AMD in the fourth quarter of 2024.

------

<u>[**Table of Contents**](#i3110ff974c884b0fab8eec36c8e490a0_7)</u>

For each of the three and six months ended June 30, 2024 we recognized $11.4 million in impairments of intangible assets as a result of classifying AMD as held-for-sale. In our held-for-sale analysis we concluded the carrying value of the AMD disposal group exceeded its estimated fair value set equivalent to an expected sale price; as such we fully impaired all long-lived assets. There was no equivalent activity for the three and six months ended June 30, 2025.

NeueCare's depreciation and amortization decreased $0.5 million and $1.5 million for the three and six months ended June 30, 2025 as compared to the same periods in 2024. The decrease is a result of a decrease in intangible asset amortization expense recognized in the three and six months ended June 30, 2025 due to the AMD intangibles impairment that occurred in the second quarter of 2024.

---

| | | | | |
|:---|:---|:---|:---|:---|
| ***NeueSolutions*** | | | | |
| *($ in thousands)* | **Three Months Ended<br>June 30,** | **Three Months Ended<br>June 30,** | **Six Months Ended<br>June 30,** | **Six Months Ended<br>June 30,** |
| **Statement of income (loss) and operating data:** | **2025** | **2024** | **2025** | **2024** |
| Revenue: |  |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Capitated revenue | $1125 | $— | $1125 | $— |
| &nbsp;&nbsp;&nbsp;&nbsp;ACO REACH revenue | 115339 | 149802 | 239379 | 321613 |
| &nbsp;&nbsp;&nbsp;&nbsp;Service revenue | 3546 | 2273 | 7116 | 4358 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**Total segment revenue** | 120010 | 152075 | 247620 | 325971 |
| Operating expenses |  |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Medical Costs | 112914 | 147258 | 239199 | 319323 |
| &nbsp;&nbsp;&nbsp;&nbsp;Operating Costs | 4542 | 4420 | 8859 | 9183 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**Total operating expenses** | 117456 | 151678 | 248058 | 328506 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**Operating income (loss)** | $2554 | $397 | $(438) | $(2535) |

---

NeueSolutions had $1.1 million of capitated revenue for the three and six months ended June 30, 2025 from our participation in the MSSP beginning January 1, 2025.

NeueSolutions' ACO REACH revenue decreased $34.5 million, or 23.0% for the three months ended June 30, 2025 as compared to the same period in 2024. NeueSolutions's ACO REACH revenue decreased $82.2 million, or 25.6% for the six months ended June 30, 2025 compared to the same period in 2024. This decrease is attributable to a decrease of approximately 10,000 beneficiaries aligned to our REACH ACOs as of June 30, 2025 compared to the same period in 2024. See Note 12, *ACO REACH*, for additional information regarding our remaining performance obligation based on the most recent benchmark data.

NeueSolutions' service revenue increased $1.3 million and $2.8 million for the three and six months ended June 30, 2025 as compared to the same periods in 2024. The increase in service revenue was driven by revenue from our enablement services contracts.

NeueSolutions' medical costs decreased by $34.3 million and $80.1 million for the three and six months ended June 30, 2025 as compared to the same periods in 2024, respectively. This decrease is attributable to a decrease of approximately 10,000 beneficiaries aligned to our REACH ACOs as of June 30, 2025 compared to the same period in 2024.

NeueSolutions' operating costs remained relatively flat for the three and six months ended June 30, 2025 as compared to the same periods in 2024.

**Liquidity and Capital Resources**

We assess our liquidity in terms of our ability to generate adequate amounts of cash to meet current and future needs. Our expected primary uses on a short-term and long-term basis are for geographic and service offering expansion, acquisitions, and

------

<u>[**Table of Contents**](#i3110ff974c884b0fab8eec36c8e490a0_7)</u>

other general corporate purposes. We have historically funded our operations and acquisitions primarily through the sale of preferred stock, sales of our common stock and debt financing arrangements.

We believe that the existing cash and investments will not be sufficient to satisfy our anticipated cash requirements for the next twelve months following the date the condensed consolidated financial statements contained in this Quarterly Report on Form 10-Q are issued. In response to these conditions, management continues to implement plans to drive positive operating cash flow and achieve the requirements in the existing debt agreements to access additional liquidity. However, the Company may not be able to access other tranches of the loan and security agreement with Hercules Capital, Inc., and may not be able to recapture through dividends additional cash from its regulated insurance entities, as these matters are all subject to conditions that are not fully within the Company's control. In the event the Company is unable to access this additional liquidity or take other management actions, among other potential consequences, the Company forecasts that it will be unable to satisfy its obligations. As a result, the Company has concluded that management's plans do not alleviate substantial doubt about the Company's ability to continue as a going concern.

Our expected primary short-term uses of cash include risk adjustment payable principal and interest and ongoing run out disbursements for medical claims and provider settlements related to our regulated insurance entities, the ACO REACH performance year obligation, remaining obligation to the deconsolidated entity, and other general and administrative costs. Our long-term cash requirements primarily include operating lease obligations, redeemable noncontrolling interest and ongoing general and administrative expenses.

Cash and investment balances held at regulated insurance entities are subject to regulatory restrictions and can only be accessed through dividends declared to the non-regulated parent company, pending regulatory approval, or through reimbursements related to administrative services agreements with the parent company. The parent Company received $23.5 million of dividends from the regulated insurance entities in surplus capital positions during the six months ended June 30, 2025, $15.0 million of which was contributed to other regulated insurance subsidiaries. The company declared $28.2 million of dividends from the regulated insurance entities to the parent company during the six months ended June 30, 2024.

In accordance with the terms of the repayment agreements with CMS, the Company must remit to CMS all surplus funds hereafter released from the regulated insurance entities, through dividends declared, within 30 calendar days of receipt of such funds.

The regulated legal entities are required to hold certain minimum levels of risk-based capital and surplus to satisfy regulatory requirements. As of June 30, 2025, we were out of compliance with the minimum levels for certain of our regulated insurance legal entities within our Bright HealthCare-Commercial segment.

**Indebtedness** 

On August 4, 2023, the Company entered into a Credit Agreement (as amended, supplemented, restated or otherwise modified from time to time, the "2023 Credit Agreement"), among the Company, NEA and the lenders from time to time party thereto (together with NEA and each of their respective successors and assigns, the "Lenders") to provide for a credit facility pursuant to which, among other things, the lenders have provided $60.0 million delayed draw term loan commitments. The Company may borrow delayed draw term loans under such commitments at any time and from time to time on or prior to the date that is nine months after the effective date of the 2023 Credit Agreement, subject to the satisfaction or waiver of customary conditions. Borrowings under the 2023 Credit Agreement accrue interest at a rate per annum of 15.00%, payable quarterly in arrears at the Company's election, subject to limitations set forth in the Fourth Waiver (as defined below) in respect of cash payments under the 2023 Credit Agreement, either in cash or "in kind" by adding the amount of accrued interest to the principal amount of the outstanding loans under the 2023 Credit Agreement. The 2023 Credit Agreement contains covenants that, among other things, restrict the ability of the Company and its subsidiaries to make certain restricted payments, incur additional debt, engage in certain asset sales, mergers, acquisitions or similar transactions, create liens on assets, engage in certain transactions with affiliates, change its business or make investments.

In connection with the 2023 Credit Agreement, on August 4, 2023, the Company and the Lenders entered into a warrantholders agreement setting forth the rights and obligations of the Company and the Lenders as holders (in such capacity, the "Holders")

------

<u>[**Table of Contents**](#i3110ff974c884b0fab8eec36c8e490a0_7)</u>

of the warrants to acquire shares of Common Stock at an exercise price of $0.01 per share (the "Warrants"), and providing for the issuance of the Warrants to purchase up to 1,656,789 shares of Common Stock.

On October 2, 2023, the Company, the Existing Lender, and California State Teachers' Retirement System, as an incremental lender (the "New Lender"), entered into Incremental Amendment No. 1 to the 2023 Credit Agreement to provide for a commitment increase by the New Lender under the 2023 Credit Agreement. Loans under Incremental Amendment No. 1 have the same terms as loans under the original term loan commitments provided by the Existing Lender.

In connection with Incremental Amendment No. 1, on October 2, 2023, the Company and the New Lender entered into the 2023 Warrantholders Agreement setting forth the rights and obligations of the Company and the New Lender as a holder of Warrants, and providing for the issuance of the Warrants to purchase up to 176,724 shares of Common Stock. As of the date of this report no warrants are available to be issued under the 2023 Warrantholders Agreement. See Note 4, *Borrowings and Common Stock Warrants*, for additional information regarding the 2023 Credit Agreement, Incremental Amendment No. 1 and the 2023 Warrantholders Agreement.

On April 8, 2024, the Company and NEA, New Enterprise Associates 17, L.P., New Enterprise Associates 16, L.P. and New Enterprise Associates 15, L.P. (collectively, the "NEA Lenders") entered into Incremental Amendment No. 2 ("Incremental Amendment No. 2") to the 2023 Credit Agreement to provide for a term loan commitment increase in an aggregate principal amount of up to $30.0 million by the NEA Lenders under the 2023 Credit Agreement. Loans under Incremental Amendment No. 2 of the 2023 Credit Agreement have the same terms as loans under the original term loan commitments provided by NEA.

On June 21, 2024, in conjunction with closing on the Hercules Credit Agreement (as defined below), the Company entered into an amendment ("Amendment No. 3") to the 2023 Credit Agreement (as amended to date, the "Amended 2023 Credit Agreement") to modify the maturity date of the 2023 Credit Agreement to be August 31, 2028, 91 days subsequent to the maturity of the Hercules Credit Agreement.

As of June 30, 2025, we had $96.4 million of long-term borrowings under the Amended 2023 Credit Agreement. There are no additional available borrowings under the Amended 2023 Credit Agreement.

In connection with Incremental Amendment No. 2, on April 8, 2024, the Company and the NEA Lenders entered into the 2024 NEA Warrantholders Agreement setting forth the rights and obligations of the Company and the NEA Lenders as holders of the warrants to acquire up to 1,113,563 shares of Common Stock at an exercise price of $0.01 per share, and providing for the issuance of warrants. As of the date of this report no warrants are available to be issued under the 2024 NEA Warrantholders Agreement. See Note 4, *Borrowings and Common Stock Warrants*, for additional information regarding the 2023 Credit Agreement, Incremental Amendment No. 2 and the 2024 NEA Warrantholders Agreement.

On June 21, 2024, the Company entered into a loan and security agreement (the "Hercules Credit Agreement"), among the Company and Hercules Capital, Inc. ("Hercules") to provide for a credit facility pursuant to which, among other things, Hercules has provided up to four tranches of term loans in an aggregate principal amount of $150.0 million, which mature on June 1, 2028. The four tranches are as follows:

*Tranche 1:* $30,000,000 term loan at closing on June 21, 2024.

*Tranche 2:* up to $25,000,000 term loan was available from November 10 – December 31, 2024 subject to the following conditions: (i) the Company achieved the "Consolidation Condition" or the "2025 Stars Condition" (each as defined in the Hercules Credit Agreement), and (ii) the absence of a material adjustment to the expected payment amount of the "Consolidation and Adjustment Escrow Amount" after giving effect to the "CHP Enrollee Adjustment", if any (each as defined in the Hercules Credit Agreement); in each case, as approved by Hercules in its reasonable discretion.

*Tranche 3:* up to $45,000,000 term loan, plus the undrawn Tranche 2 commitment, if any, that will be available from February 15 – September 15, 2025 subject to the following conditions: (i) the Company has satisfied in full the "CMS Settlement" and the "ACO REACH Deficit Obligation" (each as defined in the Hercules Credit Agreement), and (ii) after the draw down in full of the available "Tranche 3 Advances", the loan parties maintain "Qualified Cash" (as

------

<u>[**Table of Contents**](#i3110ff974c884b0fab8eec36c8e490a0_7)</u>

defined in the Hercules Credit Agreement) in an amount greater than or equal to $22,500,000; in each case as approved by Hercules in its reasonable discretion.

*Tranche 4:* up to $50,000,000 term loan, plus the aggregate sum of the undrawn previous commitments, if any, that was available from June 21, 2024 and ending on June 1, 2027, upon further approval by Hercules's investment committee.

In connection with executing the Hercules Credit Agreement, on June 21, 2024, the Company and each of the lenders under the Hercules Credit Agreement entered into warrant agreements setting forth the rights and obligations of the Company and such lenders as holders of the warrants to acquire up to an aggregate of 1,250,000 shares of Common Stock at an exercise price of $0.01 per share, and providing for the issuance of warrants. See Note 4, *Borrowings and Common Stock Warrants*, for additional information regarding the Hercules Credit Agreement and the Hercules Warrantholders Agreement.

The 2023 Warrantholders Agreement and 2024 NEA Warrantholders Agreement contain a Dilutive Issuance provision providing for additional warrants to be issued in the event of issuance of warrants with a market price lower than that of August 29, 2023, in the case of the 2023 Warrantholders Agreement, and April 30, 2024, in the case of the 2024 NEA Warrantholders Agreement. An additional 41,158 warrants were issued under the 2023 Warrantholders Agreement and 2024 NEA Warrantholders Agreement resulting from the issuance of 225,000 warrants under the Hercules Warrantholders Agreements on June 21, 2024.

On October 29, 2024, the Company entered into a Unit Purchase Agreement with Medical Practice Holding Company, LLC, RRD Healthcare, LLC ("RRD") ("Seller"), Centrum and the other parties named therein (the "Centrum Transaction"), pursuant to which we purchased RRD's remaining 25% equity interest in Centrum for a total consideration of $102.0 million, which included a secured promissory note ("Centrum Promissory Note") we issued in the principal amount of $64.0 million bearing a cash interest rate of 6% per annum, payable monthly. It is due on October 29, 2028 and all or any portion may be prepaid at any time without penalty or premium. This note is secured by second priority liens on substantially all assets of the Company and its subsidiaries.

As part of the Centrum Transaction, NeueHealth agreed to pay the former holders of the P-Unit Awards, on behalf of RRD, $2.0 million due in 2025 and another $6.0 million due in 2028 in return for the cancellation of the P-Unit Awards. As of March 31, 2025, NeueHealth paid $1.0 million of the principal due to the former holders of the P-Unit Awards.

As of June 30, 2025, we had letters of credit of $14.4 million, as well as surety bonds of $19.5 million. On our Condensed Consolidated Balance Sheets, $24.3 million of the cash and cash equivalents and $13.9 million of short-term investments are restricted as collateral to our undrawn letters of credit and surety bonds.

**Preferred Stock Financing**

On January 3, 2022, we issued 750,000 shares of the Series A Preferred Stock, par value $0.0001 per share, for an aggregate purchase price of $750.0 million. We used a portion of the proceeds to repay in full our $155.0 million of outstanding borrowings under the 2021 Credit Agreement on January 4, 2022.

On October 17, 2022, we issued 175,000 shares of the Series B Preferred Stock, par value $0.0001 per share, for an aggregate purchase price of $175.0 million.

For additional information on the Series A and Series B Preferred Stock, see Note 6, *Redeemable Convertible Preferred Stock*, in our condensed consolidated financial statements of this Quarterly Report on Form 10-Q.

**Cash and Investments**

As of June 30, 2025, we had $212.9 million in cash and cash equivalents and $21.5 million in short-term investments across our continuing and discontinued operations. As of June 30, 2025, we had no long-term investments across our continuing and discontinued operations.

------

<u>[**Table of Contents**](#i3110ff974c884b0fab8eec36c8e490a0_7)</u>

As of June 30, 2025, we had non-regulated cash and cash equivalents of $131.6 million. As of June 30, 2025, we had $13.9 million non-regulated short-term and no non-regulated long-term investments. Of the $131.6 million non-regulated cash and cash equivalents, $24.3 million is restricted as collateral to our letters of credit and surety bonds. The entirety of the $13.9 million non-regulated short-term investments is restricted as collateral to our financial guarantees.

As of June 30, 2025, we had regulated insurance entity cash and cash equivalents of $81.3 million and short-term investments of $7.5 million. As of June 30, 2025, we had no regulated insurance entity long-term investments.

**Cash Flows**

The following table presents a summary of our cash flows for the periods shown:

---

| | | |
|:---|:---|:---|
| | **Six Months Ended<br>June 30,** | **Six Months Ended<br>June 30,** |
|<br>*($ in thousands)* | **2025** | **2024** |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Net cash used in operating activities | $(23875) | $(77148) |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Net cash provided by investing activities | 54650 | 189281 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Net cash used in financing activities | (3249) | (225955) |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Net increase (decrease) in cash and cash equivalents | $27526 | $(113822) |
| Cash and cash equivalents at beginning of period | $185405 | $375280 |
| **Cash and cash equivalents at end of period** | $212931 | $261458 |

---

***Operating Activities***

During the six months ended June 30, 2025, net cash used in operating activities decreased by $53.3 million compared to the six-month period ended June 30, 2024. This fluctuation is primarily attributable to larger payments on our outstanding medical costs payable and risk adjustment principal balances associated with our discontinued operations during the six months ended June 30, 2024 as compared to the equivalent period ended June 30, 2025.

***Investing Activities***

During the six months ended June 30, 2025, net cash provided by investing activities decreased by $134.6 million compared to the six-month period ended June 30, 2024. The cash provided by investing activities during the six months ended June 30, 2024 is primarily attributable to the non-contingent net proceeds received for the sale of our California Medicare Advantage business that closed effective January 1, 2024. The cash provided by investing activities during the six months ended June 30, 2025 is primarily attributable to receipt of the Consolidation and Escrow Adjustment that was a contingent portion of the net proceeds from the sale of our California Medicare Advantage business that was released to NeueHealth on March 17, 2025.

***Financing Activities***

During the six months ended June 30, 2025, net cash used in financing activities decreased by $222.7 million compared to the six months ended June 30, 2024. This cash used in financing activities during the six months ended June 30, 2024 is primarily attributable to the payoff of our short-term debt using a portion of the proceeds from the sale of our California Medicare Advantage business during the six months ended June 30, 2024. The cash used in financing activities during the six months ended June 30, 2025 is primarily attributable to distributions to noncontrolling interest holders as well as a $1.0 million payment of principal to the former P-Unit holders.

------

<u>[**Table of Contents**](#i3110ff974c884b0fab8eec36c8e490a0_7)</u>

**Critical Accounting Policies and Estimates**

As of June 30, 2025, there had been no material changes to the critical accounting policies and estimates used in the preparation of our condensed consolidated financial statements as described in the 2024 Form 10-K under "Management's Discussion and Analysis of Financial Condition and Results of Operations – Critical Accounting Policies and Estimates."

**Recently Adopted Accounting Pronouncements**

For a description of recently issued accounting pronouncements, see Note 1, *Organization and Basis of Presentation*, in our condensed consolidated financial statements of this Quarterly Report on Form 10-Q.

------

<u>[**Table of Contents**](#i3110ff974c884b0fab8eec36c8e490a0_7)</u>

**ITEM 3. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK**

Not applicable.

 **ITEM 4. CONTROLS AND PROCEDURES** 

**Limitations on Effectiveness of Controls and Procedures**

In designing and evaluating our disclosure controls and procedures, management recognizes that any controls and procedures, no matter how well designed and operated, can provide only reasonable assurance of achieving the desired control objectives. In addition, the design of disclosure controls and procedures must reflect the fact that there are resource constraints, and that management is required to apply judgment in evaluating the benefits of possible controls and procedures relative to their costs.

**Evaluation of Disclosure Controls and Procedures**

We maintain disclosure controls and procedures (as defined in Rules 13a-15(e) and 15d-15(e) under the Securities Exchange Act of 1934 (the "Exchange Act")) that are designed to provide reasonable assurance that information required to be disclosed by us in reports that we file or submit under the Exchange Act is (i) recorded, processed, summarized and reported within the time periods specified in SEC rules and forms; and (ii) accumulated and communicated to our management, including our principal executive officer and principal financial officer, as appropriate to allow timely decisions regarding required disclosure.

In connection with the filing of this quarterly report on Form 10-Q, our management, with the participation of our Chief Executive Officer and Chief Financial Officer, evaluated the effectiveness of our disclosure controls and procedures as of June 30, 2025. Based on that evaluation, our Chief Executive Officer and Chief Financial Officer concluded that disclosure controls and procedures were effective at the reasonable assurance level as of June 30, 2025.

**Changes in Internal Control over Financial Reporting**

There have been no changes in our internal control over financial reporting (as defined in Rules 13a-15(f) and 15d-15(f) under the Exchange Act) during the quarter ended June 30, 2025 that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.

------

<u>[**Table of Contents**](#i3110ff974c884b0fab8eec36c8e490a0_7)</u>

**PART II. OTHER INFORMATION**

**Item 1. Legal Proceedings**

Other than the matters described in Note 8, *Commitments and Contingencies*, we are not presently a party to any litigation the outcomes of which, we believe, if determined adversely to us, would individually or taken together have a material adverse effect on our business, operating results, cash flows, or financial condition.

**Item 1A. Risk Factors**

This Quarterly Report on Form 10-Q should be read in conjunction with the risk factors included in our 2024 Form 10-K and our other filings with the SEC. There have been no material changes to the risk factors disclosed under the heading "Risk Factors" in our 2024 Form 10-K.

**Item 2. Unregistered Sales of Equity Securities, Use of Proceeds, and Issuer Purchases of Equity Securities**

None.

**Item 3. Defaults upon Senior Securities**

None.

**Item 4. Mine Safety Disclosures**

Not applicable.

**Item 5. Other Information**

None.

------

<u>[**Table of Contents**](#i3110ff974c884b0fab8eec36c8e490a0_7)</u>

**Item 6. Exhibits**

**EXHIBIT INDEX**

---

| | |
|:---|:---|
| **Exhibit<br>Number** | **Description** |
| 2.1 | <u>[Agreement and Plan of Merger, dated as of December 23, 2024, by and among NH Holdings 2025, Inc., NH Holdings Acquisition 2025, Inc. and NeueHealth, Inc. (incorporated by reference to Exhibit 2.1 filed with the Registrant's Current Report on Form 8-K filed on December 23, 2024).](https://www.sec.gov/Archives/edgar/data/1671284/000110465924131382/tm2431820d1_ex2-1.htm)</u> |
| 3.1 | <u>[Ninth Amended and Restated Certificate of Incorporation of NeueHealth, Inc. (incorporated by reference to Exhibit 4.1 filed with the Registrant's Registration Statement on Form S-8 filed on June 28, 2021)](https://www.sec.gov/Archives/edgar/data/1671284/000110465921086281/tm217793d23_ex4-1.htm)</u> |
| 3.2 | <u>[Certificate of Designations of Series A Convertible Perpetual Preferred Stock of NeueHealth, Inc. (incorporated by reference to Exhibit 3.1 filed with the Registrant's Current Report on Form 8-K filed on January 3, 2022)](https://www.sec.gov/Archives/edgar/data/1671284/000167128422000003/ex31_preferredclosingxexa.htm)</u> |
| 3.3 | <u>[Certificate of Amendment to the Certificate of Designations of Series A Convertible Perpetual Preferred Stock of NeueHealth, Inc. (incorporated by reference to Exhibit 3.1 filed with the Registrant's Current Report on Form 8-K filed on October 18, 2022)](https://www.sec.gov/Archives/edgar/data/1671284/000167128422000056/ex31_101722seriesacodamend.htm)</u> |
| 3.4 | <u>[Certificate of Designations of Series B Convertible Perpetual Preferred Stock of NeueHealth, Inc. (incorporated by reference to Exhibit 3.2 filed with the Registrant's Current Report on Form 8-K filed on October 18, 2022)](https://www.sec.gov/Archives/edgar/data/1671284/000167128422000056/ex32_101722seriesbcod.htm)</u> |
| 3.5 | <u>[Certificate of Amendment to the Ninth Amended and Restated Certificate of Incorporation of NeueHealth, Inc. (incorporated by reference to Exhibit 3.1 filed with the Registrant's Current Report on Form 8-K filed on May 25, 2023)](https://www.sec.gov/Archives/edgar/data/1671284/000167128423000021/ex31certificateofamendment.htm)</u> |
| 3.6 | <u>[Certificate of Amendment to the Ninth Amended and Restated Certificate of Incorporation of NeueHealth, Inc. (incorporated by reference to Exhibit 3.1 filed with the Registrant's Current Report on Form 8-K filed on January 24, 2024)](https://www.sec.gov/Archives/edgar/data/1671284/000167128424000013/ex31_charteramendmentjan20.htm)</u> |
| 3.7 | <u>[Fourth Amended and Restated Bylaws of NeueHealth, Inc. (incorporated by reference to Exhibit 3.2 filed with the Registrant's Current Report on Form 8-K filed on January 24, 2024)](https://www.sec.gov/Archives/edgar/data/1671284/000167128424000013/ex32_bhg-4thamendedandrest.htm)</u> |
| 31.1\* | <u>[Certifications pursuant to Section 302 of the Sarbanes-Oxley Act of 2002](ex311_ceocertificationx063.htm)</u> |
| 31.2\* | <u>[Certifications pursuant to Section 302 of the Sarbanes-Oxley Act of 2002](ex312_cfocertificationx063.htm)</u> |
| 32.1\* | <u>[Certifications pursuant to Section 906 of the Sarbanes-Oxley Act of 2002](ex321_ceocertificationx063.htm)</u><sup>(1)</sup> |
| 32.2\* | <u>[Certifications pursuant to Section 906 of the Sarbanes-Oxley Act of 2002](ex322_cfocertificationx063.htm)</u><sup>(1)</sup> |
| 101 | The following financial information from our Quarterly Report on Form 10-Q for the second quarter of fiscal 2025, filed with the SEC on August 7, 2025, formatted in Inline Extensible Business Reporting Language ("iXBRL") |
| 104 | Cover Page Interactive Data File (formatted as iXBRL and embedded within Exhibit 101) |

---

\* Filed herewith

† Management contract or compensatory plan or arrangement.

<sup>(1)</sup> The certifications in Exhibits 32.1 and 32.2 to this Quarterly Report on Form 10-Q shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, and shall not be incorporated by reference into any filing or other document pursuant to the Securities Act of 1933, as amended, except as shall be expressly set forth by specific reference in such filing or document.

------

<u>[**Table of Contents**](#i3110ff974c884b0fab8eec36c8e490a0_7)</u>

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

---

| | | |
|:---|:---|:---|
| | **NEUEHEALTH, INC.** | **NEUEHEALTH, INC.** |
| Dated: August 7, 2025 | By: | /s/ G. Mike Mikan |
|  | Name: | G. Mike Mikan |
|  | Title: | Vice Chairman, President and Chief Executive Officer |
|  |  | (Principal Executive Officer) |
|  | By: | /s/ Jay Matushak |
|  | Name: | Jay Matushak |
|  | Title: | Chief Financial Officer |
|  |  | (Principal Financial Officer) |
|  | By: | /s/ Jeffrey J. Scherman |
|  | Name: | Jeffrey J. Scherman |
|  | Title: | Chief Accounting Officer |
|  |  | (Principal Accounting Officer) |

---

## Exhibit 31.1

**EXHIBIT 31.1**

**CERTIFICATION OF THE CHIEF EXECUTIVE OFFICER**

**PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002**

<u>Certifications</u>

I, G. Mike Mikan, certify that:

1. I have reviewed this Quarterly report on Form 10-Q of NeueHealth, Inc. (the "registrant");

2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

4. The registrant's other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;c) Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;d) Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and

5. The registrant's other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions):

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.

---

| |
|:---|
| Dated: August 7, 2025 |
| /s/ G. Mike Mikan |
| G. Mike Mikan |
| Vice Chairman, President and Chief Executive Officer |

---

## Exhibit 31.2

**EXHIBIT 31.2**

**CERTIFICATION OF THE CHIEF FINANCIAL OFFICER**

**PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002**

<u>Certifications</u>

I, Jay Matushak, certify that:

1. I have reviewed this Quarterly report on Form 10-Q of NeueHealth, Inc. (the "registrant");

2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

4. The registrant's other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;c) Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;d) Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and

5. The registrant's other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions):

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.

---

| |
|:---|
| Dated: August 7, 2025 |
| /s/ Jay Matushak |
| Jay Matushak |
| Chief Financial Officer |

---

## Exhibit 32.1

**Exhibit 32.1**

**CERTIFICATION PURSUANT TO&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**

**18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO**

**SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002**

**Certification of Principal Executive Officer**

In connection with the report of NeueHealth, Inc. (the "Company") on Form 10-Q for the period ended June 30, 2025 as filed with the Securities and Exchange Commission on the date hereof (the "Report"), I, G. Mike Mikan, certify, pursuant to 18 U.S.C. § 1350, as adopted pursuant to § 906 of the Sarbanes-Oxley Act of 2002, that to my knowledge:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(1)The Report fully complies with the requirements of section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(2)The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

---

| |
|:---|
| Dated: August 7, 2025 |
| /s/ G. Mike Mikan |
| G. Mike Mikan |
| Vice Chairman, President and Chief Executive Officer |

---

## Exhibit 32.2

**Exhibit 32.2**

**CERTIFICATION PURSUANT TO**

**18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO**

**SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002**

**Certification of Principal Financial Officer**

In connection with the report of NeueHealth, Inc. (the "Company") on Form 10-Q for the period ended June 30, 2025 as filed with the Securities and Exchange Commission on the date hereof (the "Report"), I, Jay Matushak, certify, pursuant to 18 U.S.C. § 1350, as adopted pursuant to § 906 of the Sarbanes-Oxley Act of 2002, that to my knowledge:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(1)The Report fully complies with the requirements of section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(2)The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

---

| |
|:---|
| Dated: August 7, 2025 |
| /s/ Jay Matushak |
| Jay Matushak |
| Chief Financial Officer |

---

<br>